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Abstract
Background: Vasopressin/oxytocin (VP/OT)-type neuropeptides are well known for their roles as regulators of
diuresis, reproductive physiology and social behaviour. However, our knowledge of their functions is largely based
on findings from studies on vertebrates and selected protostomian invertebrates. Little is known about the roles of
VP/OT-type neuropeptides in deuterostomian invertebrates, which are more closely related to vertebrates than
protostomes.
Results: Here, we have identified and functionally characterised a VP/OT-type signalling system comprising the
neuropeptide asterotocin and its cognate G-protein coupled receptor in the starfish (sea star) Asterias rubens, a
deuterostomian invertebrate belonging to the phylum Echinodermata. Analysis of the distribution of asterotocin
and the asterotocin receptor in A. rubens using mRNA in situ hybridisation and immunohistochemistry revealed
expression in the central nervous system (radial nerve cords and circumoral nerve ring), the digestive system
(including the cardiac stomach) and the body wall and associated appendages. Informed by the anatomy of
asterotocin signalling, in vitro pharmacological experiments revealed that asterotocin acts as a muscle relaxant in
starfish, contrasting with the myotropic actions of VP/OT-type neuropeptides in vertebrates. Furthermore, in vivo
injection of asterotocin had a striking effect on starfish behaviour—triggering fictive feeding where eversion of the
cardiac stomach and changes in body posture resemble the unusual extra-oral feeding behaviour of starfish.
Conclusions: We provide a comprehensive characterisation of VP/OT-type signalling in an echinoderm, including a
detailed anatomical analysis of the expression of both the VP/OT-type neuropeptide asterotocin and its cognate
receptor. Our discovery that asterotocin triggers fictive feeding in starfish provides important new evidence of an
evolutionarily ancient role of VP/OT-type neuropeptides as regulators of feeding in animals.
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Background
Physiological processes and behaviour are controlled
and regulated by a huge variety of neuronally secreted
peptide signalling molecules (neuropeptides), which
typically exert their effects on target cells by binding
to cognate G-protein coupled receptors (GPCRs) [1–
3]. Amongst the most intensely studied neuropeptides
are vasopressin (VP) and oxytocin (OT). VP and OT
are structurally related neuropeptides that were ori-
ginally discovered based on their peripheral actions as
pituitary hormones in mammals. VP is a cyclic and
amidated nonapeptide (CYFQNCPRG-NH2; with a di-
sulphide bridge between the cysteines) that acts as an
antidiuretic and increases blood pressure, whereas OT
(CYIQNCPLG-NH2) causes uterine contraction and
lactation [4]. VP and OT are also released within the
brain, and the discovery that they are key players in
neural mechanisms of social and reproductive behav-
iour in humans and other animals has led to a revo-
lutionary growth in interest in these neuropeptides as
potential therapeutic agents for the treatment of dis-
orders such as autism, social anxiety and schizophre-
nia [5].
Phylogenetic analysis has revealed that neuropeptide
signalling systems are evolutionarily ancient. Thus, the
evolutionary origin of at least 30 neuropeptide families
(including VP/OT-type) can be traced back to the bila-
terian common ancestor of deuterostomes (vertebrates
and invertebrate chordates, hemichordates, echino-
derms) and protostomes (e.g. arthropods, nematodes,
molluscs, annelids) [3, 6, 7]. Definitive evidence of the
antiquity of VP/OT-type neuropeptides was first ob-
tained with the purification and sequencing of VP/OT-
type neuropeptides from insect and molluscan species
[8, 9]. More recently, comparative analysis of genome/
transcriptome sequence data has enabled the discovery
of genes encoding VP/OT-type neuropeptides and their
putative cognate receptors in many bilaterian animal
phyla. Furthermore, this has enabled comparative ana-
lysis of the physiological roles of VP/OT-type neuropep-
tides in species belonging to different phyla [10–12].
Interestingly, this has provided evidence that not only
the structures but also the functions of VP/OT-type neu-
ropeptides are evolutionarily conserved. Thus, a VP/OT-
type neuropeptide in insects (inotocin) has a VP-like role
in regulating urine production [13], whereas a VP/OT-
type neuropeptide in the mollusc Lymnaea stagnalis has
an OT-like role in regulating reproductive physiology
[14, 15]. Furthermore, application of reverse genetic
techniques in the nematode Caenorhabditis elegans re-
vealed that VP/OT-type signalling is required for normal
mating behaviour in this species [16], consistent with
the actions of VP and OT in regulating mating behav-
iour and reproductive physiology in mammals [5].
Comparative investigation of the physiological roles of
VP/OT-type neuropeptides has largely focused on verte-
brates and selected protostomian invertebrates, as
highlighted above. What are missing are insights from
the Ambulacraria (echinoderms and hemichordates),
deuterostomian invertebrates that are more closely re-
lated to chordates (including vertebrates) than proto-
stomes [17]. A gene encoding the VP/OT-type
neuropeptide echinotocin has been identified in the sea
urchin Strongylocentrotus purpuratus, and in vitro
pharmacological studies revealed that echinotocin acts
as a muscle contractant in sea urchins, consistent with
the myostimulatory actions of VP and OT in mammals
[18]. However, a more comprehensive analysis of the
biochemistry, anatomy and physiology of VP/OT-type
signalling has yet to be reported for an echinoderm spe-
cies. To address this issue, here we have performed an
extensive experimental analysis of VP/OT-type signalling
in an emerging model system for neuropeptide re-
search—the starfish (sea star) Asterias rubens. Sequen-
cing of the neural transcriptome of A. rubens has
enabled the identification of transcripts encoding at least
40 neuropeptide precursor proteins [19]. Furthermore,
we have begun to characterise selected neuropeptide sys-
tems in A. rubens in detail. For example, our recent ex-
perimental analysis of gonadotropin-releasing hormone
(GnRH)-related neuropeptides in A. rubens provided im-
portant new insights into the evolution of neuropeptide
signalling in the animal kingdom [20, 21]. Using the star-
fish A. rubens as a model system, here we report a de-
tailed functional characterisation of VP/OT-type
neuropeptide signalling in an echinoderm.
Results
Molecular characterisation of a VP/OT-type signalling
system in the starfish A. rubens
A transcript encoding a 147-residue precursor protein
comprising an N-terminal signal peptide, a VP/OT-type
neuropeptide (asterotocin) and C-terminal neurophysin
domain (Fig. 1a), was identified previously by analysis of
A. rubens neural transcriptome sequence data [19], and
its sequence was then confirmed by cDNA cloning and
sequencing [22]. Informed by the known structures of
VP/OT-type neuropeptides [13, 15, 23, 24], we synthe-
sised the predicted mature asterotocin peptide—
CLVQDCPEG-NH2, an amidated cyclic nonapeptide
with a disulphide bridge between the cysteine residues at
positions 1 and 6 (Fig. 1b). Mass spectrometric analysis
of extracts of radial nerve cords from A. rubens revealed
the presence of a peptide with identical properties to
synthetic asterotocin (Additional file 1). A comparison
of asterotocin with VP/OT-type neuropeptides in other
taxa reveals that it is unusual in having an acidic residue
(Glu; E) at position 8 (Fig. 1c).
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To identify a candidate receptor for asterotocin,
BLAST analysis of A. rubens neural transcriptome data
was performed using known VP/OT-type receptors from
other species as queries. A 2710-bp transcript (contig
1122053) encoding a 428-residue protein was identified,
and phylogenetic analysis confirmed that it is an ortho-
log of VP/OT-type receptors that have been charac-
terised in other taxa (Fig. 2a). A cDNA encoding this
receptor was cloned and sequenced (Additional file 2;
GenBank accession number MK279533) and then co-
expressed with the promiscuous Gα16 protein in Chin-
ese hamster ovary (CHO) cells stably expressing the
Ca2+-sensitive luminescent apo-aequorin protein. Syn-
thetic asterotocin caused concentration-dependent lumi-
nescence in CHO cells transfected with the A. rubens
VP/OT-type receptor but had no effect on CHO cells
transfected with an empty vector (Fig. 2b). The EC50
value for asterotocin as a ligand for the receptor was
5.7 × 10−8 M, consistent with the potency of VP/OT-type
neuropeptides as ligands for their cognate receptors in
other taxa [26–29]. We also tested the starfish neuro-
peptide NGFFYamide, which is a paralog of asterotocin
[25, 30, 31], and human vasopressin (VP) and human
oxytocin (OT). These three peptides did not cause sig-
nificant receptor activation, even at the highest peptide
concentration tested (10−4 M), demonstrating the speci-
ficity of the A. rubens VP/OT-type receptor for asteroto-
cin as a ligand (Fig. 2c). Having identified molecular
components of the VP/OT-type neuropeptide signalling
pathway in A. rubens, asterotocin and its cognate G-
protein coupled receptor, the asterotocin receptor, we
then investigated the anatomical distribution of these
molecules in A. rubens to gain insights into the physio-
logical roles of VP/OT-type signalling in this species.
The anatomy of starfish
To facilitate the interpretation of the expression patterns
of asterotocin and its receptor in A. rubens, in Fig. 3, we
show schematics of starfish anatomy. The starfish ner-
vous system comprises five radial nerve cords linked by
a circumoral nerve ring (Fig. 3a, b), which have two dis-
tinct regions (Fig. 3c): the hyponeural region that con-
tains motoneurons and the ectoneural region that is
thought to largely comprise sensory neurons and inter-
neurons [32]. Along the length of each arm, flanking the
radial nerve cords are rows of tube feet (Fig. 3a, b) that
enable locomotor activity. The entrance to the digestive
system (mouth) is located on the underside of the cen-
tral disc region and is surrounded by a contractile peri-
stomial membrane (Fig. 3a). Extending aborally from the
mouth is a short tubular oesophagus leading into a large,
highly folded and evertible cardiac stomach. Above the
cardiac stomach is a smaller pyloric stomach, followed
by a short intestine, a rectum (with associated rectal
caeca) and a tiny opening (anus) on the aboral surface of
the central disc (Fig. 3a). Paired digestive organs located
in each arm (pyloric caeca) are connected to the pyloric
stomach by pyloric ducts (Fig. 3a, b). Paired reproductive
organs (testes or ovaries) are also located in each arm
(Fig. 3a, b). The body wall comprises calcite ossicles and
Fig. 1 Asterotocin: a vasopressin/oxytocin (VP/OT)-type neuropeptide in the starfish Asterias rubens. a Amino acid sequence of the A. rubens
asterotocin precursor with the predicted signal peptide shown in blue, a predicted cleavage site shown in green, the asterotocin peptide shown
in red with a C-terminal glycine that is a putative substrate for amidation shown in orange and the neurophysin domain shown in purple. b
Structure of the mature asterotocin peptide as determined by mass spectrometry (Additional file 1), with a disulphide bridge between the two
cysteine residues and with C-terminal amidation. c Clustal-X alignment of asterotocin (A_rub) with VP/OT-type peptides from other animals
reveals that the pair of cysteine residues (asterisks) is conserved in all of the peptides, whereas other residues are conserved in a subset of the
peptides. Full species names within each taxonomic group (Ambulacraria, Chordata and Protostomia) and corresponding accession numbers for
the peptide sequences are listed in Table S1 of Additional file 3
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associated appendages for defence (pedicellariae and
spines) and gas exchange (papulae). The internal surface
of the body wall is lined by a coelomic epithelium
(Fig. 3a, b), with underlying layers of longitudinally
orientated and circularly orientated muscle. In an aboral
sagittal position, the longitudinal body wall muscle layer
is thickened to form an apical muscle that facilitates arm
flexion.
Fig. 2 Phylogenetic identification and deorphanisation of an A. rubens VP/OT-type receptor. a Maximum likelihood tree showing that a VP/OT-
type receptor identified by BLAST analysis of A. rubens transcriptome sequence data (boxed) is positioned within a clade comprising VP/OT-type
receptors from other taxa. NPS/NG peptide/CCAP-type receptors are paralogs of VP/OT-type receptors [25]. Phylogenetic analyses of bilaterian
neuropeptide receptors have shown that GnRH/AKH/ACP/CRZ-type receptors are closely related to VP/OT-type receptors and NPS/NG peptide/
CCAP-type receptors [6]. Therefore, GnRH/AKH/ACP/CRZ-type receptors were included as an outgroup in the phylogenetic tree. The scale bar
indicates amino acid substitutions per site, and bootstrap values are shown at nodes. Species where activation of the VP/OT-type receptor by a
cognate VP/OT-type neuropeptide has been demonstrated experimentally (including A. rubens, see b) are labelled with an asterisk. Full species
names and accession numbers for the receptor sequences are listed in Table S2 of Additional file 3. b Asterotocin (black circles) causes
concentration-dependent activation of the A. rubens VP/OT-type receptor, demonstrated by measuring Ca2+-induced luminescence in CHO-K1
cells expressing aequorin, and transfected with the promiscuous G-protein Gα16 and the A. rubens VP/OT-type receptor (CHO-K1/G5A-ArVPOTR
cells); EC50 = 5.7 × 10
−8 M. CHO-K1 cells transfected with empty pcDNA vector (black square) were used as a negative control and do not exhibit
luminescence when exposed to asterotocin. c Comparison of the relative luminescence responses of CHO-K1/G5A-ArVPOTR cells when exposed
to asterotocin or the related peptides NGFFYamide (a paralog of asterotocin in A. rubens), human vasopressin or human oxytocin, all at a
concentration of 10−4 M. Luminescence responses in the presence of vasopressin, oxytocin and NGFFYamide were not significantly higher than
the basal media control (P = 0.5, P = 0.25, P = 0.25, respectively; Wilcoxon signed-rank test; n = 9)
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Localisation of asterotocin precursor transcripts and
asterotocin in A. rubens
To investigate the distribution of asterotocin precur-
sor transcripts in A. rubens, mRNA in situ hybridisa-
tion (ISH) methods were employed. To enable
immunohistochemical (IHC) visualisation of the ma-
ture neuropeptide derived from the asterotocin pre-
cursor, we generated a rabbit antiserum to asterotocin
(Additional file 4). To determine the specificity of this
antiserum, it was tested on the sections of arms from
A. rubens in parallel with antiserum that had been
pre-absorbed with the antigen peptide. The majority
of immunostaining observed was abolished by anti-
serum pre-absorption, but there was some residual
staining (Additional file 5). Therefore, antibodies
affinity-purified from the antiserum were used for im-
munohistochemical analysis of asterotocin expression
in A. rubens.
In the nervous system, asterotocin precursor-
expressing cells and asterotocin-immunoreactive cells
were revealed in the epithelial layer of the ectoneural re-
gion of the radial nerve cords and circumoral nerve ring,
with immunostained processes in the underlying neuro-
pile; no expression was detected in the hyponeural re-
gion (Fig. 4a–d). Asterotocin precursor-expressing cells
(Fig. 4e) and asterotocin-immunoreactive processes
(Fig. 4f ) were also revealed in the marginal nerve cords,
which are located lateral to the outer row of tube feet in
each arm. In the tube feet, asterotocin precursor-
expressing cells were revealed in the disc region (Fig. 4g),
while asterotocin immunoreactivity was revealed in the
basal nerve ring and basal region of the longitudinal
nerve tract (Fig. 4h).
Asterotocin precursor-expressing cells were revealed
in several regions of the digestive system, including the
peristomial membrane (Fig. 4i), oesophagus (Fig. 4j),
Fig. 3 Starfish anatomy. a Schematic vertical section of the central disc and the proximal region of an arm. b Schematic transverse section of an
arm. c Schematic transverse section of a radial nerve cord. Abbreviations: a, anus; am, apical muscle; amp, ampulla; conr, circumoral nerve ring; cs,
cardiac stomach; cut, cuticle; ec, ectoneural region; g, gonad; gcc, general coelomic cavity; hy, hyponeural region; m, mouth; md, madreporite;
mn, marginal nerve; o, ossicle; p, papula; pc, pyloric caecum; pd., pyloric duct; ped, pedicellaria; pm, peristomial membrane; ps, pyloric stomach;
rc, rectal caecum; rca, ring canal; rn, radial nerve; rw, radial water vascular canal; sp., spine; sc, stone canal; tb, Tiedemann’s body; tf, tube foot
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Fig. 4 Localisation of asterotocin in A. rubens using in situ hybridisation (ISH) and immunohistochemistry (IHC). a Asterotocin precursor transcript-
expressing cells (AstPtc) in a radial nerve cord (black arrowheads) and tube feet (white arrowheads). Inset shows the absence of staining with
sense probes. b Asterotocin-immunoreactive (Ast-ir) cells (arrowheads in inset) and fibres (white asterisks) in a radial nerve cord. c AstPtc in the
circumoral nerve ring (arrowheads and inset). d Ast-ir cells (arrowheads) and fibres (white asterisks) in the circumoral nerve ring. e AstPtc in
marginal nerve. f Ast-ir fibres in marginal nerve. g AstPtc in tube foot disc. h Ast-ir in the basal nerve ring (black arrow) and longitudinal nerve
tract (grey arrow) of a tube foot. i AstPtc in the peristomial membrane. j AstPtc in the oesophagus. k Ast-ir in the peristomial membrane (square
bracket) and oesophagus. l AstPtc in the cardiac stomach. m Ast-ir in the cardiac stomach. n AstPtc in the pyloric stomach. o AstPtc in a pyloric
duct. p Ast-ir in the pyloric stomach. q AstPtc in the coelomic epithelium of the body wall. r Ast-ir in the coelomic basiepithelial nerve plexus of
body wall. s Ast-ir in the basiepithelial nerve plexus of the apical muscle. t AstPtc in a papula. u Ast-ir in a papula. v AstPtc in the body wall. w
Ast-ir in the body wall. x AstPtc in a pedicellaria. y Ast-ir in a pedicellaria. z AstPtc in a spine. z’ Ast-ir in an ambulacral spine. Abbreviations: AM,
apical muscle; BNR, basal nerve ring; BNP, basiepithelial nerve plexus; CMLNP, circular muscle layer nerve plexus; CBNP, coelomic basiepithelial
nerve plexus; CE, coelomic epithelium; CT, collagenous tissue; Di, disc; Ec, ectoneural region; EE, external epithelium; Hy, hyponeural region; LNT,
longitudinal nerve tract; Lu, lumen; MN, marginal nerve; ML, mucosal layer; MuL, muscle layer; Oes, oesophagus; Pa, papula; RHS, radial hemal
sinus; TF, tube foot; VML, visceral muscle layer. Scale bars: a, a inset, h, l, m, n, o, p, u = 60 μm; b, d, g, z’ = 40 μm; i, j, l inset, p inset, t, w, x =
30 μm; B inset, c, d inset, e, k, n inset, o inset, s, v, y, z = 20 μm; c inset, f, m inset, q, r = 10 μm
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cardiac stomach (Fig. 4l), pyloric stomach (Fig. 4n) and
pyloric duct (Fig. 4o), with stained cells typically located
in the upper mucosal layer just below the basiepithelial
nerve plexus (see insets of Fig. 4l, n, o). Accordingly,
asterotocin immunoreactivity was revealed in the basie-
pithelial nerve plexus in several regions of the digestive
system, including the peristomial membrane and
oesophagus (Fig. 4k), cardiac stomach (Fig. 4m) and pyl-
oric stomach (Fig. 4p).
In the body wall, asterotocin precursor-expressing cells
and asterotocin-immunoreactive cells were revealed in
the coelomic epithelium (Fig. 4q, r), with immunostained
processes in the underlying coelomic lining (Fig. 4r).
Asterotocin precursor mRNA was not detected in the
apical muscle, but immunoreactivity was revealed in the
apical muscle (Fig. 4s). Asterotocin precursor-expressing
cells were detected in the coelomic lining of papulae
(Fig. 4t), and accordingly, asterotocin-immunoreactive
processes were revealed in the underlying nerve plexus
(Fig. 4u). Additionally, asterotocin precursor-expressing
cells are present in the external epithelium of the body
wall (Fig. 4v), and associated appendages, including pedi-
cellariae (Fig. 4x) and ambulacral spines (Fig. 4z). Con-
sistent with these findings, asterotocin-immunoreactive
fibres were revealed in the basiepithelial nerve plexus of
the external body wall (Fig. 4w), pedicellariae (Fig. 4y)
and ambulacral spines (Fig. 4z’).
Localisation of asterotocin receptor expression in A.
rubens
Employing the same techniques used to analyse the dis-
tribution of asterotocin, localisation of asterotocin recep-
tor expression was similarly determined using in situ
hybridisation and immunohistochemistry. For immuno-
histochemical analysis, a guinea pig antiserum to the
asterotocin receptor was generated, and antibodies to
the antigen peptide were affinity-purified from the anti-
serum (Additional file 4). Cell bodies expressing astero-
tocin receptor mRNA transcripts were revealed in the
ectoneural epithelial layer of the radial nerve cords
(Fig. 5a) and circumoral nerve ring (Fig. 5c). Consistent
with this finding, asterotocin receptor-immunoreactive
cells were detected in the ectoneural epithelium, with
stained processes in the underlying neuropile of the ra-
dial nerve cords (Fig. 5b) and circumoral nerve ring
(Fig. 5d). Asterotocin receptor mRNA-expressing cells
were revealed in the marginal nerves (Fig. 5e), and ac-
cordingly, immunostaining was also observed in cells
and processes in the marginal nerves (Fig. 5f ). Cells ex-
pressing asterotocin receptor mRNA were revealed in
tube feet discs (Fig. 5g), and consistent with this finding,
immunostained processes were revealed in the basal
nerve ring of tube feet, with stained processes also
extending into a longitudinal fibre tract that extends ab-
orally from the basal nerve ring (Fig. 5h).
In the digestive system, asterotocin receptor mRNA-
expressing cells were revealed in the mucosal layer
(Fig. 5i) and the coelomic epithelial lining of the visceral
muscle layer of the cardiac stomach (Fig. 5i, inset). De-
tection of asterotocin receptor immunoreactivity in the
cardiac stomach seemed to be sensitive to the decalcifi-
cation methods used for processing the whole central
disc region. Therefore, to avoid the decalcification step,
cardiac stomach preparations were fixed in situ and then
dissected from the central disc prior to embedding in
paraffin wax. Using this method, stained processes were
detected in the basiepithelial nerve plexus (Fig. 5j) and
in the visceral muscle layer of the cardiac stomach
(Fig. 5j, inset).
Asterotocin receptor mRNA-expressing cells were de-
tected in the coelomic epithelium of the body wall
(Fig. 5k), and accordingly in Fig. 5l, an asterotocin
receptor-immunoreactive cell can be seen in the coel-
omic epithelium in close proximity to the apical muscle
but no asterotocin receptor expression was detected in
the apical muscle. Asterotocin receptor mRNA-
expressing cells (Fig. 5m) and asterotocin receptor-
immunoreactive cells (Fig. 5n) were detected in the ex-
ternal epithelial layer of the body wall. Asterotocin re-
ceptor expression was also detected in body wall-
associated appendages, including the papulae (Fig. 5o),
spines (Fig. 5p) and pedicellariae (Fig. 5q).
To enable a direct comparison of the distribution of
asterotocin immunoreactivity and asterotocin receptor
immunoreactivity, double-labelling immunofluorescence
methods were employed. This revealed that asterotocin
and the asterotocin receptor are expressed in the same
regions of the nervous system but appear to be largely
expressed in different cells and processes. Thus, in the
radial nerve cords, distinct groups of cells exhibiting
asterotocin immunoreactivity or asterotocin receptor
immunoreactivity can be observed in the ectoneural epi-
thelium. Accordingly, in the ectoneural neuropile, a ‘salt
and pepper’ pattern of immunolabelling is observed,
with asterotocin-immunoreactive fibres interspersed
with less abundant asterotocin receptor-immunoreactive
fibres and with little evidence of co-localisation (Fig. 6a).
Likewise, in the marginal nerves (Fig. 6b) and basal
nerve ring of the tube foot (Fig. 6c), distinct populations
of fibres expressing asterotocin or the asterotocin recep-
tor are observed in close proximity. In the cardiac stom-
ach, asterotocin immunoreactivity can be observed in
the basiepithelial nerve plexus and mucosa, while astero-
tocin receptor immunoreactivity can be observed in the
basiepithelial nerve plexus, mucosa and visceral muscle
layer. As in the radial nerve cords, marginal nerves and
basal nerve ring, analysis of immunostaining in the
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basiepithelial nerve plexus of the cardiac stomach indi-
cates that asterotocin and asterotocin receptor proteins
are largely localised in different fibre populations but
often in close proximity to each other (Fig. 6d).
With regard to the sub-cellular localisation of the
asterotocin receptor, it is noteworthy that asterotocin re-
ceptor immunoreactivity can be seen in the cytoplasm of
ectoneural cell bodies (Fig. 6b), which probably reflects
Fig. 5 Localisation of asterotocin receptor in A. rubens using in situ hybridisation (ISH) and immunohistochemistry (IHC). a Asterotocin receptor
transcript-expressing cells (AstRtc) in a radial nerve cord (black arrowheads) and tube feet (white arrowheads). Inset shows the absence of
staining with sense probes. b AstR-immunoreactive (AstR-ir) cells (black arrowhead) and processes (arrows and in inset) in a radial nerve cord.
Stained fibres in the adjacent tube foot (white arrow). c AstRtc in the circumoral nerve ring. d AstR-ir cells (arrowheads) and fibres (arrow) in the
circumoral nerve ring. e AstRtc in a marginal nerve. f AstR-ir cell (arrowhead) and stained process (black arrow) in a marginal nerve. Stained fibres
in the adjacent tube foot (white arrow). g AstRtc in a tube foot (black arrowhead). h Ast-ir in a tube foot. i AstRtc in the cardiac stomach. j AstR-ir
in the mucosal layer (white arrowhead), basiepithelial nerve plexus (black arrowhead) and visceral muscle layer (black arrow; inset) of the cardiac
stomach. k AstRtc in the coelomic epithelium of the body wall. l AstR-ir cell in the coelomic epithelium of the body wall. m AstRtc in the external
epithelium of the body wall. n AstR-ir cell in the external epithelium of the body wall. o AstRtc in a papula. p AstR-ir cells in an ambulacral spine.
q AstR-ir cells in a pedicellaria. Abbreviations: BNR, basal nerve ring; BNP, basiepithelial nerve plexus; CMLNP, circular muscle layer nerve plexus;
Ce, coelom; CBNP, coelomic basiepithelial nerve plexus; CT, collagenous tissue; Di, disc; Ec, ectoneural region; EE, external epithelium; Hy,
hyponeural region; Lu, lumen; MN, marginal nerve; ML, mucosal layer; Pa, papula; RHS, radial hemal sinus; TF, tube foot; VML, visceral muscle layer.
Scale bars: a, a inset, b, c, g, h, o, p, q = 60 μm; d, e, j = 30 μm; c inset, f, g inset, n = 20 μm; b inset, e inset, f inset, i, i inset, j inset, k, l,
m, o = 10 μm
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the presence of receptor proteins in the endoplasmic
reticulum and/or Golgi apparatus before they are tar-
geted to the plasma membrane. Functional asterotocin
receptors located in the plasma membrane are likely to
be present in the processes of cells that express the
asterotocin receptor, and accordingly, asterotocin
receptor-immunoreactive processes (red) can be seen
intermingled amongst asterotocin-immunoreactive pro-
cesses (green) in the ectoneural neuropile (Fig. 6a, b).
However, the resolution of the microscopy was not suffi-
cient to determine if the asterotocin receptor immunore-
activity is specifically associated with the plasma
membrane in the tiny cross-sectional profiles of neur-
onal processes.
Asterotocin causes relaxation of the cardiac stomach and
apical muscle preparations in vitro
Both vasopressin and oxytocin cause contraction of the
smooth muscle in mammals [4], and we have reported
previously that the VP/OT-type neuropeptide echinoto-
cin causes contraction of tube foot and oesophagus
preparations from the sea urchin Echinus esculentus
(Phylum Echinodermata) [18]. Therefore, it was of inter-
est here to investigate the effects of asterotocin on
muscle preparations from A. rubens. Informed by the ex-
pression of asterotocin and its receptor in the cardiac
stomach and tube feet, and the localisation of asteroto-
cin immunoreactivity in the apical muscle, asterotocin
was tested on in vitro preparations of these three organs.
Interestingly, we found that asterotocin causes relaxation
of the cardiac stomach and apical muscle preparations
(Fig. 7), but it had no observable effect on the tube feet
(data not shown). Asterotocin is a potent relaxant of the
cardiac stomach, with the peptide causing reversal of
KCl-induced contraction at concentrations as low as 3 ×
10−11 M. The largest mean relaxing effect was observed
at ~ 10−7 M, with desensitisation often observed at
higher concentrations (Fig. 7a, b). Previous studies have
revealed that the SALMFamide neuropeptide S2
(SGPYSFNSGLTF-NH2) also acts as a relaxant of cardiac
stomach preparations in A. rubens [33, 34], and there-
fore, it was of interest to compare the efficacy of astero-
tocin and S2. Testing both peptides at a concentration
of 10−7 M, it was observed that the magnitude of the
Fig. 6 Comparison of asterotocin and asterotocin receptor expression in A. rubens using double-labelling fluorescence immunohistochemistry.
Comparison of the distribution of asterotocin immunoreactivity (Ast-ir; green) and asterotocin receptor immunoreactivity (AstR-ir; red) in A. rubens
reveals ‘salt and pepper’ patterns of labelling consistent with expression largely in different, but often adjacent, populations of cells/processes. In
the few instances where labelling appears yellow/orange, this could be due to the co-localisation of asterotocin and the asterotocin receptor in
processes or alternatively it may simply reflect where asterotocin-containing fibres happen to be positioned directly above asterotocin receptor
containing fibres. a Radial nerve cord showing Ast-ir cells (yellow arrowheads) and AstR-ir cells (white arrowheads) in the ectoneural epithelium
and Ast-ir processes (yellow arrow) and AstR processes (white arrow) in the ectoneural neuropile. b Marginal nerve; AstR-ir cells (white
arrowhead) in the epithelial layer and both Ast-ir processes (yellow arrow) and AstR-ir processes (white arrow) in the underlying neuropile. c Disc
region of a tube foot; Ast-ir processes (yellow arrow) and AstR-ir processes (white arrow) in the basal nerve ring. d Cardiac stomach; Ast-ir
processes (white arrowhead) and AstR-ir processes (blue arrow) in the basiepithelial nerve plexus and mucosa, while in the visceral muscle layer,
only AstR-ir is present (white arrow). Abbreviations: BNR, basal nerve ring; BNP, basiepithelial nerve plexus; CS, cardiac stomach; CT, collagenous
tissue; Ec, ectoneural; Lu, lumen; ML, mucosal layer; TF, tube foot; VML, visceral muscle layer. Scale bars: d = 30 μm; c = 20 μm; a, b = 10 μm
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relaxing action of asterotocin was ~ 3–4 times larger
than the effect of S2 (Fig. 7c; raw data for the graph are
available in Additional file 6: Table S1). In contrast to
the potency of asterotocin as a relaxant of cardiac stom-
ach preparations, the relaxing effect of asterotocin on
apical muscle preparations was only observed with high
peptide concentrations (1 μM; Fig. 7d), with maximal re-
laxation occurring within 20 s of application (Fig. 7d,
inset; raw data for the graph are available in Add-
itional file 6: Table S2).
Asterotocin triggers cardiac stomach eversion in vivo
Starfish feed by firstly prying apart the bivalve shells of
prey (e.g. mussels) with their tube feet and then everting
their cardiac stomach out of their mouth and over the
exposed digestible soft tissues [35, 36]. In order for the
cardiac stomach to be everted, it must be in a relaxed
state, and therefore, neuropeptides that cause cardiac
stomach relaxation in vitro are potential mediators of
eversion in vivo. We have previously reported that injec-
tion of 100 μl 10−3 M S2 into the perivisceral coelom of
A. rubens triggers cardiac stomach eversion [34], and
here we investigated if asterotocin also triggers cardiac
stomach eversion in this species. Because the relaxing ef-
fect of asterotocin on the cardiac stomach in vitro was
consistently observed at concentrations ranging from
10−9 to 10−6 M (Fig. 7b), experiments were designed to
test asterotocin over a similar concentration range in
vivo. Informed by analysis of the volume of the pervisc-
eral coelomic fluid in A. rubens (~ 5–15ml for animals
used in this study), 10 μl of 10−6–10−3 M asterotocin
(n = 5 for each concentration) was injected into the
Fig. 7 Asterotocin causes relaxation of in vitro cardiac stomach and apical muscle preparations from A. rubens. a Representative recording
showing that asterotocin causes relaxation of a cardiac stomach preparation. Seawater supplemented with KCl (3 × 10−2 M) was used to induce
contraction of the cardiac stomach prior to the application of asterotocin. The relaxing effect of asterotocin is reversed when the preparation is
washed with KCl-supplemented seawater. b Graph showing the concentration-dependent relaxing effect of asterotocin on cardiac stomach
preparations at concentrations ranging from 3 × 10−11 M to 10−6 M. The responses are expressed as the mean relative percentage (± SEM; n = 16)
of the maximal relaxing effect of asterotocin in each preparation. c Representative recording from a cardiac stomach preparation that compares
the relaxing effects of asterotocin and the SALMFamide-type neuropeptide S2, both at 10−7 M. As in a, the cardiac stomach preparation was pre-
contracted with KCl-supplemented seawater prior to the application of the neuropeptides. Inset compares the effects of asterotocin and S2 on
cardiac stomach preparations at a concentration of 10−7 M, expressed as mean percentages (± SEM; n = 5) with the relaxing effect of S2 defined
as 100%. The relaxing effect of asterotocin is significantly larger than the effect S2 (Mann-Whitney U test; P = 0.0079; n = 5). d Representative
recording showing that asterotocin (10−6 M) causes relaxation of an apical muscle preparation. 10−6 M acetylcholine (ACh) was used to induce
contraction of the apical muscle preparation prior to the application of asterotocin. Following washing of the preparation with artificial seawater,
it returns to its basal relaxed state. Inset shows the mean percentage (± SEM; n = 4) reversal of 10−6 M ACh-induced contraction of apical muscle
preparations caused by 10−6 M asterotocin over a 50-s period after peptide administration
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perivisceral coelom of starfish to achieve an estimated
concentration of 10−9 to 10−6 M in vivo. For comparison,
other starfish were injected with 10 μl water (n = 5) or
10 μl 10−3 M S2 (n = 5). No stomach eversion was ob-
served in animals injected with water, whereas cardiac
stomach eversion occurred in 0%, 80%, 100% and 100%
of the animals injected with 10 μl 10−6–10−3 M asteroto-
cin (Fig. 8a). Interestingly, cardiac stomach eversion was
not observed in animals injected with 10 μl of 10−3 M
S2, consistent with its lower potency/efficacy as a cardiac
stomach relaxant in vitro by comparison with asteroto-
cin (Fig. 7c).
To investigate more specifically the dynamics of the in
vivo effect of asterotocin, we performed experiments
where the effect of injection of 10 μl 10−3 M asterotocin
was video recorded, quantifying cardiac stomach ever-
sion as a percentage of the area of the central disc region
at 30 s intervals over a period of 10 min from the time of
injection. In this experiment, cardiac stomach eversion
was observed in 13 out of 15 animals tested, with the
remaining 2 animals displaying mouth opening but no
eversion. Quantification of responses in the 13 animals
where asterotocin-induced cardiac stomach eversion was
observed (Fig. 8b) revealed that eversion typically started
at approximately 2 min and 30 s after the injection and
mean maximal eversion occurred by 8min after the in-
jection of asterotocin. Video recordings of representative
water-injected (control) and asterotocin-injected animals
are shown in Additional file 7, and images captured from
these videos are shown in Fig. 8c.
Fig. 8 In vivo injection of asterotocin triggers cardiac stomach eversion in A. rubens. a Dose-dependent effect of asterotocin in inducing cardiac
stomach eversion. The graph shows the percentage of animals (n = 5 per group) that exhibit cardiac stomach eversion when injected with 10 μl
asterotocin at concentrations ranging from 10−6 M to 10−3 M, by comparison with 10 μl of the starfish neuropeptide S2 (10−3 M) or 10 μl of water.
Stomach eversion occurred in 100%, 100% and 80% of the animals injected with 10−5 M, 10−4 M and 10−3 M asterotocin, respectively, but
stomach eversion was not observed in any of the animals injected with 10−6 M asterotocin, 10−3 M S2 or water. b Temporal dynamics of
asterotocin-induced (10 μl of 10−3 M) cardiac stomach eversion. The graph shows mean area (± SEM; n = 13) of the cardiac stomach everted
expressed as the percentage of the area of the central disc region at 30-s intervals over a 10-min period following injection of asterotocin. c
Images from video recordings of the experiment in b showing a representative water-injected (control) starfish (i–iii) and a representative
asterotocin-injected starfish (iv–vi) at 0 min (immediately after injection), after 5 min and after 10 min. The area of the cardiac stomach everted is
shown with a dashed line in v and vi. The representative video recordings used to generate the images in c are in Additional file 7
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Asterotocin causes changes in body posture that affect
righting behaviour
While investigating the effect of asterotocin in triggering
cardiac stomach eversion in A. rubens, we observed that
arm flexion occurred in many of the animals injected
with asterotocin but not in control animals injected with
water. The magnitude of this effect was variable, how-
ever, with flexion of one or more arm tips occurring
(Fig. 9a (i)), flexion of one or two whole arms occurring
(Fig. 9a (ii)) or flexion of all five arms occurring (Fig. 9a
(iii)). This is interesting because, relevant to the effect of
asterotocin in triggering cardiac stomach eversion, arm
flexion occurs in starfish when they adopt a humped
feeding posture to prey on mussels and other marine in-
vertebrates [36] (Fig. 9a (iv)). To assess the impact of the
effect of asterotocin on body posture in A. rubens, we
tested the effect of asterotocin on the righting behaviour
of starfish. Righting occurs if starfish are upturned so
that their oral surface is uppermost, with animals twist-
ing their arms so that the tube feet can latch onto the
substratum and then somersaulting to bring the entire
oral surface back into contact with the substratum [37,
38]. Following a 1-week period of starvation to normal-
ise the physiological condition of animals, the effect of
asterotocin injection and water injection on starfish
righting behaviour was compared. A representative ex-
periment is shown in Fig. 9b, where it can be seen that
the water-injected animal has righted within 120 s,
whereas by this time point, the asterotocin-injected ani-
mal still has its oral surface uppermost and cardiac
stomach eversion can also be seen. Righting in the
asterotocin-injected animal is not completed until 222 s
after injection. Analysis of data obtained from all of the
animals tested in this experiment revealed that the mean
time taken for righting to occur in water-injected starfish
was 89 ± 11 s whereas the time taken for righting to
occur in animals injected with asterotocin was signifi-
cantly longer, with a mean of 217 ± 31 s (Fig. 9c (i)). Be-
cause of inter-individual variation in the time taken for
righting to occur, the percentage mean difference in
righting time with and without injection of water or
asterotocin was also calculated (Fig. 9c (ii)). The mean
percentage righting time difference between water-
injected and non-injected starfish was − 11 ± 7%, while
asterotocin-injected animals exhibited a 127 ± 36% in-
crease in the righting time.
In a separate experiment, the effect of asterotocin on
righting behaviour was investigated by comparison with
S2, a neuropeptide which like asterotocin induces car-
diac stomach eversion but which does not induce the
changes in posture seen in animals injected with astero-
tocin (Fig. 9d). For this experiment, the animals were
starved for a longer period (4 weeks), and the mean time
for righting to occur in non-injected animals was longer
(345 ± 35 s) compared to the previous experiment
(105 ± 8 s), which probably reflects the longer starvation
period prior to testing. The mean righting time for S2-
injected animals (312 ± 40 s) was not significantly differ-
ent to the mean righting time of water-injected animals
(341 ± 59 s), whereas the mean righting time of
asterotocin-injected animals was significantly longer
(1110 ± 162 s) (Fig. 9d (i)). Furthermore, by comparing
the righting time before and after the injection, the
mean percentage differences following the injection of
water and S2 were not statistically significant: − 1.8 ±
13% and 15 ± 12%, respectively. In contrast, the mean
percentage righting time difference following injection of
asterotocin was 414 ± 104% (Fig. 9d (ii)). In conclusion,
these experiments indicate that the effect of asterotocin
on starfish righting behaviour is attributable to its effect
on posture.
Discussion
Investigation of the actions of VP/OT-type neuropep-
tides in chordates, and protostomian invertebrates has
revealed conserved and evolutionarily ancient roles in
the regulation of processes such as reproduction and
water homeostasis [10–12]. To obtain new insights into
the evolution of VP/OT-type neuropeptide function in
the animal kingdom, here we functionally characterised
VP/OT-type signalling in an echinoderm—the starfish A.
rubens. Investigation of VP/OT-type neuropeptide func-
tion in echinoderms is of special interest because they
are deuterostomian invertebrates and therefore are more
closely related to chordates than protostomes. Further-
more, the derived radially symmetrical body plan of
adult echinoderms provides a unique context for the in-
vestigation of neuropeptide function in the Bilateria [39].
The vasopressin/oyxtocin-type neuropeptide asterotocin
acts as a muscle relaxant and triggers fictive feeding in
starfish
Investigation of the in vitro pharmacological actions of
the VP/OT-type neuropeptide asterotocin in starfish re-
vealed an unusual functional characteristic in that it acts
as a muscle relaxant, whereas in other taxa, VP/OT-type
neuropeptides typically cause muscle contraction [15,
18, 40–44]. More specifically, we discovered that astero-
tocin is a potent relaxant of in vitro preparations of the
cardiac stomach from starfish. This was of interest from
a physiological/behavioural perspective because relax-
ation of the cardiac stomach occurs naturally when star-
fish evert their stomach out of their mouth to feed
extra-orally on prey (e.g. mussels) [35, 36]. Previous
studies have revealed that neuropeptides belonging to
the echinoderm SALMFamide neuropeptide family also
act as cardiac stomach relaxants in vitro and can trigger
cardiac stomach eversion when injected in vivo [33, 34].
Odekunle et al. BMC Biology           (2019) 17:60 Page 12 of 23
Therefore, here we compared the effects of in vivo injec-
tion of asterotocin and the SALMFamide neuropeptide
S2. This revealed that asterotocin also triggers cardiac
stomach eversion in starfish, but it is much more effect-
ive than S2. Furthermore, the observation of starfish that
had been injected with asterotocin revealed that it also
induced postural changes resembling the humped pos-
ture that starfish adopt when feeding on prey [36]. Strik-
ingly, this effect of asterotocin on starfish body posture
was so powerful that it prevented upturned starfish from
righting themselves normally. Thus, injection of astero-
tocin induces fictive feeding in starfish, triggering both
Fig. 9 Asterotocin induces a feeding-like posture that impairs righting behaviour in A. rubens. a Asterotocin-induced changes in posture in A.
rubens: (i) soon after injection, with arm tips curled upwards; (ii) within 10 min, with one or more arms curled upwards; and (iii) within 20min,
with all arms curled upwards and resembling the natural feeding posture (iv). b Images from representative videos show that asterotocin-injected
starfish (vi–xi) take longer to right than water-injected starfish (i–v). c Effect of asterotocin on righting behaviour following 1-week starvation. (i)
Mean (± SEM) righting time in asterotocin-injected starfish is 217 ± 31 s (n = 10) and significantly longer than in non-injected (105 ± 8 s; n = 20,
pooled data) and water-injected starfish (89 ± 11 s; n = 10); (P < 0.0001; one-way ANOVA with Dunnett’s multiple comparisons test). (ii) Mean
percentage righting time difference between water-injected and non-injected starfish is − 11 ± 7%, whereas between asterotocin-injected and
non-injected starfish, it is 127 ± 36% (P = 0.0005; Mann-Whitney U test; n = 10). d Testing effects of asterotocin and S2 on righting behaviour
following 4-week starvation. (i) Mean (± SEM) righting times in water-injected animals (341 ± 59 s; n = 20) and in S2-injected animals (312 ± 40 s;
n = 20) are significantly different. Asterotocin causes a significant increase in righting time (1110 ± 162 s; n = 20) compared with non-injected (n =
60, pooled from the three treated groups), water-injected and S2-injected animals (P < 0.0001; one-way ANOVA with Dunnett’s multiple
comparisons test). (ii) Mean percentage righting time difference between non-injected and water-injected animals (− 1.8 ± 13%) and between
non-injected and S2-injected animals (15 ± 12%) are not statistically significant, but there is statistical significance between non-injected and
asterotocin-injected animals (414 ± 104%; P < 0.0001; one-way ANOVA with Dunnett’s multiple comparisons test; n = 20)
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cardiac stomach eversion and adoption of a body pos-
ture resembling that which occurs during natural feeding
on prey. Based on these findings, we propose that the
VP/OT-type neuropeptide asterotocin has a physio-
logical role as a neural regulator of the unusual extra-
oral feeding behaviour of starfish.
Mechanisms of asterotocin signalling in starfish
To gain insights into the molecular and cellular mecha-
nisms of asterotocin signalling in starfish, we identified
an A. rubens G-protein coupled receptor which is an
ortholog of VP/OT-type receptors that have been char-
acterised pharmacologically in other taxa. Furthermore,
we discovered that asterotocin acts as a potent ligand
(EC50 = 5.7 × 10
−8 M) for the A. rubens VP/OT-type re-
ceptor when the receptor is heterologously expressed in
CHO cells. Thus, the molecular components of a VP/
OT-type neuropeptide signalling system, asterotocin and
a G-protein coupled asterotocin receptor, were identified
biochemically in A. rubens. Importantly, this enabled
analysis of the distribution of molecular components of
the VP/OT-type signalling pathway in A. rubens, providing
an anatomical framework for interpretation of the in vitro
and in vivo effects of asterotocin in this species. Further-
more, it is noteworthy that this is the first study to deter-
mine the anatomical expression patterns of both a
neuropeptide and its cognate receptor in an echinoderm.
Consistent with the in vitro and in vivo effects of
asterotocin in triggering cardiac stomach relaxation and
eversion in A. rubens, respectively, cells expressing the
asterotocin precursor transcript were detected in the
mucosal layer of the cardiac stomach, and asterotocin
immunoreactivity was revealed in the basiepithelial
nerve plexus of the cardiac stomach. Accordingly, cells
expressing the asterotocin receptor transcript were de-
tected in the mucosal and visceral muscle layers of the
cardiac stomach, and asterotocin receptor immunoreac-
tivity was revealed both in the basiepithelial nerve plexus
and in the visceral muscle layer of the cardiac stomach.
Based on these expression patterns and the pharmaco-
logical effects of asterotocin in A. rubens, it can be in-
ferred that asterotocin is released physiologically by
neurons located in the mucosal layer of the cardiac
stomach and then (i) diffuses into the visceral muscle
layer to act on asterotocin receptors on muscle cells to
cause relaxation and/or (ii) acts on neural processes in
the basiepithelial nerve plexus layer to trigger release of
another neurochemical that acts directly on muscle cells
to cause relaxation.
The effect of asterotocin in inducing a posture that re-
sembles the humped feeding posture of starfish is inter-
esting because this effect has not been reported for any
other neuropeptide. It also raises questions regarding the
mechanisms by which asterotocin exerts this effect. Our
analysis of the distribution of asterotocin in the central
nervous system of A. rubens revealed that the asteroto-
cin precursor transcript and asterotocin immunoreactiv-
ity are restricted to the ectoneural regions of the radial
nerve cords and circumoral nerve ring, with no expres-
sion detected in the hyponeural region. This is note-
worthy because it is the hyponeural region that contains
the cell bodies and processes of skeletal motoneurons
[32, 45, 46]. In starfish, the skeleton comprises a net-
work of calcite ossicles that are linked by interossicular
muscles, which enable changes in body posture [47].
Consistent with the absence of asterotocin expression in
neuronal cell bodies of hyponeural motoneurons, no
asterotocin immunoreactivity was observed in the in-
nervation of the interossicular muscles. This contrasts
with other neuropeptides in starfish, such as pedal
peptide-type neuropeptides and a calcitonin-type neuro-
peptide, which are expressed by hyponeural neuronal
cell bodies and are present in the innervation of interos-
sicular muscles [48–50]. Like asterotocin, both pedal
peptide-type and calcitonin-type neuropeptides act as
muscle relaxants in starfish, but unlike asterotocin, they
do not trigger cardiac stomach eversion or a feeding
posture [48–50]. We infer from these observations that
asterotocin may induce a feeding posture in starfish by
acting within the ectoneural region of the central ner-
vous system to cause activation of downstream asteroto-
cin receptor-mediated neural mechanisms that induce
postural changes.
The distribution of asterotocin indicates that it is not
solely involved in the regulation of feeding behaviour in
starfish. For example, asterotocin and its receptor are
detected in the body wall and its associated appendages,
which is suggestive of a role in mediating local responses
to the sensory stimuli. Additionally, asterotocin is de-
tected in cells/processes associated with the apical
muscle, which is innervated by cells located in the coel-
omic epithelium that lines the inner surface of the aboral
body wall, and consistent with this pattern of expression,
asterotocin causes relaxation of apical muscle prepara-
tions in vitro. Thus, asterotocin is not dissimilar to VP/
OT-type neuropeptides that have been functionally char-
acterised in other taxa, where pleiotropic actions are in-
dicative of roles in the regulation of a variety of
physiological/behavioural processes [16, 29, 51]. It will
be of interest to examine other aspects of asterotocin
function in starfish in future studies, and not only in
adult animals but also in the free-swimming and bilat-
erally symmetrical starfish larvae. Preliminary insights
have been obtained by mapping the distribution of the
asterotocin precursor transcript in the larvae of A.
rubens, which revealed expression in cells associated with
the attachment complex that mediates larval attachment
to the substratum prior to metamorphosis [22].
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Evolution and comparative physiology of VP/OT-type
neuropeptides as regulators of feeding
Our discovery that asterotocin has such striking feeding-
related effects in starfish provides a basis to examine if
VP/OT-type neuropeptides are likewise involved in the
regulation of feeding-associated processes in other taxa.
Currently, little is known about the physiological roles of
VP/OT-type neuropeptides in other echinoderms. How-
ever, it has been reported that a VP/OT-type neuropep-
tide (echinotocin) causes contraction of in vitro
preparations of the oesophagus and tube feet in sea ur-
chins [18]. This effect of echinotocin as a muscle con-
tractant is consistent with the myoexcitatory effects of
VP/OT-type neuropeptides in many other taxa, but it
contrasts with the relaxing action of asterotocin on star-
fish muscle preparations. Thus, this highlights how un-
usual the myoinhibitory action of asterotocin is as a VP/
OT-type neuropeptide in starfish. Nevertheless, the ef-
fect of echinotocin on the sea urchin oesophagus sug-
gests that VP/OT-type neuropeptides may be generally
associated with the regulation of feeding-related pro-
cesses in echinoderms. Turning to other deuterostomian
invertebrates, currently, nothing is known about the
physiological roles of the VP/OT-type neuropeptides that
been identified by analysis of genome sequence data in
hemichordates and cephalochordates. However, a VP/
OT-type signalling system has been characterised in the
urochordate Ciona intestinalis, revealing that the VP/
OT-type receptor Ci-VP-R is expressed in the alimentary
tract [27]. In vertebrates, VP/OT-type neuropeptides are,
as highlighted above, most widely known for their effects
on reproductive physiology/behaviour and osmoregula-
tion [4, 5]. However, roles in the regulation of feeding
and/or digestive processes have been reported. Thus,
there is a substantial body of evidence that OT inhibits
feeding [52–55] and gastric motility [56, 57] in mam-
mals. Accordingly, the OT-type peptide isotocin and the
VP-type peptide vasotocin inhibit food intake in fish [58,
59]. Although the effect of asterotocin in inducing fictive
feeding in starfish contrasts with the inhibitory actions
of VP/OT-type neuropeptides on feeding in vertebrates,
our findings indicate that VP/OT-type neuropeptides are
evolutionarily ancient regulators of feeding-related pro-
cesses in the deuterostome branch of the Bilateria.
What about in the protostome branch of the Bilateria?
In the annelid Eisenia foetida, the VP/OT-type neuro-
peptide annetocin potentiates spontaneous contractions
of gut preparations, providing evidence of a role in the
regulation of digestive processes [60]. In the cephalopod
mollusc Octopus vulgaris, the VP/OT-type signalling sys-
tem has been characterised in detail and comprises two
VP/OT-type neuropeptides, octopressin (OP) and cepha-
lotocin (CT), and three cognate receptors (OPR, CTR1,
CTR2). Furthermore, OP is expressed in the regions of
the octopus nervous system involved in the control of
feeding and/or gut activity and, accordingly, OP has
myoexcitatory effects on in vitro preparations of the
octopus rectum [42, 61, 62]. However, experimental evi-
dence that OP regulates feeding behaviour in octopuses
has as yet not been reported. Interestingly, extensive
analysis of VP/OT-type signalling in the nematode C.
elegans has revealed that, in addition to a reproductive
role in the regulation of mating behaviour [16], VP/OT-
type signalling regulates gustatory associative learning in
this species [29]. Thus, both direct and indirect evidence
that VP/OT-type signalling is involved in the regulation
of feeding-related processes have been obtained from a
variety of studies on protostomes.
We infer from this phylogenetic survey of VP/OT-type
neuropeptide function that the effect of asterotocin in
triggering fictive feeding in starfish reflects an evolution-
arily ancient role of VP/OT-type neuropeptides as regu-
lators of feeding-related processes in the Bilateria. This
adds to the existing evidence of evolutionarily ancient
roles in the regulation of diuresis and reproductive pro-
cesses and reflects the pleitropy of neuropeptide func-
tion in animals. However, the extent to which
evolutionarily ancient roles of VP/OT-type neuropep-
tides as regulators of feeding, reproduction and diuresis
have been preserved in different taxa may vary consider-
ably. Therefore, further investigation of VP/OT-type
neuropeptide function in a variety of bilterian phyla and
classes will be needed to gain deeper insights into the
evolution of the physiological roles of this signalling
system.
Conclusions
Here, we have reported a comprehensive characterisa-
tion of VP/OT-type signalling in an echinoderm, the
starfish A. rubens. This has yielded striking evidence that
the VP/OT-type signalling system may be a key regulator
of the unusual extra-oral feeding behaviour of starfish.
Furthermore, when combined with previous reports of
feeding-related roles in vertebrates and protostomes, our
findings provide important new evidence that VP/OT-
type neuropeptide signalling is an ancient and evolution-
arily conserved regulator of feeding in the Bilateria.
Materials and methods
Animals
Starfish (A. rubens) were collected from the Thanet
Coast (Kent, UK) at low tide or were acquired from a
fisherman based in Whitstable (Kent, UK) and trans-
ported to the School of Biological and Chemical Sci-
ences, Queen Mary University of London. The starfish
were maintained in circulating artificial seawater at ap-
proximately 12 °C in an aquarium and were fed mussels
(Mytilus edulis). Animals ranging in diameter from 5 to
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15 cm were used for in vitro and in vivo pharmacological
experiments, whereas smaller animals (< 5 cm in diam-
eter) were used for anatomical studies. Additionally, ju-
venile specimens of A. rubens (diameter 0.5–1.5 cm)
were collected from the University of Gothenburg Sven
Lovén Centre for Marine Infrastructure (Kristineberg,
Sweden) and used for anatomical studies.
Mass spectrometric identification of the VP/OT-type
neuropeptide asterotocin in A. rubens radial nerve cord
extracts
Radial nerve cords were dissected from five adult speci-
mens of A. rubens using a method described previously
[63]. Neuropeptides were then extracted in 1 ml of 80%
acetone on ice [64]. Acetone was removed by evapor-
ation using nitrogen, with the aqueous fraction centri-
fuged at 11,300g in a MiniSpin® microcentrifuge
(Eppendorf) for 10 min, and the remaining supernatant
stored at − 80 °C. Prior to mass spectrometry (MS), the
extract was thawed (with an aliquot diluted tenfold with
0.1% aqueous formic acid) and filtered through a 0.22-
μm Costar Spin-X centrifuge tube filter (Sigma-Aldrich)
to remove particulates. In comparison with synthetic
asterotocin (PPR Ltd., Fareham, UK), the radial nerve
cord extract was analysed by nanoflow liquid chroma-
tography (LC) with electrospray ionisation (ESI) quadru-
pole time-of-flight tandem MS (nano LC-ESI-MS/MS)
using a nanoAcquity ultra performance LC (UPLC) sys-
tem coupled to a Synapt® G2 High-Definition Mass
Spectrometer™ (HDMS) (Waters Corporation) and Mas-
sLynx v4.1 SCN 908 software (Waters Corporation). The
mobile phases used for the chromatographic separation
were 0.1% aqueous formic acid (termed mobile phase A)
and 0.1% formic acid in acetonitrile (termed mobile
phase B). An aliquot containing 15 μl of the A. rubens
radial nerve cord extract was applied to a Symmetry
C18® (180 μm× 20mm, 5 μm particle size, 100 Å pore
size) trapping column (Waters Corporation) using 99.9%
mobile phase A at a flow rate of 10 μl min−1 for 3 min,
after which the fluidic flow path included the HSS T3
(75 μm× 150mm, 1.8 μm particle size, 100 Å pore size)
analytical capillary column (Waters Corporation). A lin-
ear gradient of 5–40% mobile phase B over 105 min was
utilised with a total run time of 120 min. The nanoflow
ESI source conditions utilised a 3.5-kV capillary voltage,
25 V sample cone voltage and an 80 °C source
temperature. The instrument was operated in resolution
mode (~ 20,000 measured at full width and half height).
A solution containing 500 fmol μl−1 Glu1-Fibrinopeptide
B peptide in 50% v/v aqueous acetonitrile containing
0.1% formic acid was infused via a NanoLockSpray inter-
face at a constant rate of 500 nl min−1, sampled every 60
s and used for lockmass correction (m/z 785.8426) enab-
ling accurate mass determination.
A data-dependent acquisition was performed that
would trigger an MS/MS scan on any singly charged
peptide having a mass to charge ratio (m/z) of 960.3919,
or a doubly charged peptide of m/z 480.6999, with a tol-
erance of 100 mDa allowed on the precursor m/z. MS/
MS spectra, obtained from data-dependent acquisition,
were processed using MassLynx™ software (Waters Cor-
poration). Spectra were combined and processed using
the MaxEnt 3 algorithm to generate singly charged,
monoisotopic spectra for interpretation and manual
validation.
Identification and cloning of a cDNA encoding an A.
rubens VP/OT-type receptor
To identify an A. rubens VP/OT-type receptor, the amino
acid sequence of the sea urchin (Strongylocentrotus purpur-
atus) VP/OT-type receptor [65] was submitted as a query
in a tBLASTn search of A. rubens radial nerve cord tran-
scriptome sequence data using SequenceServer software
[66]. The top hit (contig 1122053) was a 2710-bp transcript
encoding a 428-residue protein, which based on reciprocal
BLAST analysis was identified as an ortholog of the S. pur-
puratus VP/OT-type receptor. A cDNA encoding the A. ru-
bens VP/OT-type receptor was then cloned using A. rubens
radial nerve cord cDNA as a template for PCR amplifica-
tion, employing the use of primers (see Additional file 2)
that were designed using Primer3 (http://primer3.ut.ee).
The cDNA was then incorporated into the pBluescript SKII
(+) vector and sequenced (Eurofins Genomics).
Phylogenetic analysis of the A. rubens VP/OT-type
receptor
Phylogenetic analysis of the relationships between the A.
rubens VP/OT-type receptor and VP/OT-type receptors
from other species was performed using the maximum-
likelihood method. Firstly, receptor protein sequences
were aligned in MEGA7 (v.7170509) using MUltiple Se-
quence Comparison by Log-Expectation (MUSCLE)
[67]. Once aligned, poorly aligned regions were removed
using the Gblocks server (using the least stringent set-
tings) to optimise the alignment for phylogenetic ana-
lysis [68]. PhyML (version 3.0) was then used to
generate a maximum-likelihood tree [69]. The LG model
was automatically selected, and the bootstrap was manu-
ally set to 1000. FigTree version 1.4.3 (http://tree.bio.ed.
ac.uk/software/figtree/) was used to visualise and re-root
the tree generated by PhyML. NPS/CCAP/NG peptide-
type, and GnRH/AKH/ACP/CRZ-type receptor se-
quences were used as outgroups in the tree.
Testing asterotocin as a ligand for the A. rubens VP/OT-
type receptor
A pBluescript SKII (+) vector containing the A. rubens
VP/OT-type receptor cDNA as an insert (see above) was
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used as a template to amplify by PCR the open reading
frame of the VP/OT-type receptor. To accomplish this,
the oligonucleotides 5′-ggatccCACCATGACGCCCTC-
3′ (upstream) and 5′-cccgggCTACATGTGAGCG-
GAAGCA-3′ (downstream) were used as primers and
the PCR product was subcloned into the eukaryotic ex-
pression vector pcDNA 3.1+, which had been cut with
the restriction enzymes BamHI and ApaI. For the up-
stream primer, a partial Kozak translation initiation se-
quence (CACC) was introduced before the start codon
to optimise the initiation of translation.
To determine if asterotocin acts as a ligand for the A.
rubens VP/OT-type receptor, a cell-based assay was used
where Ca2+-induced luminescence is measured. For this
assay, Chinese hamster ovary (CHO-K1) cells stably ex-
pressing the Ca2+-sensitive bioluminescent GFP-
aequorin fusion protein—G5A (CHO-K1/G5A cells [70])
are co-transfected with plasmids containing a G-protein
coupled receptor cDNA insert and plasmids containing
an insert encoding the promiscuous G-protein Gα16. If
a candidate ligand activates the expressed receptor, the
promiscuous Gα16 protein triggers the activation of the
IP3 signalling pathway, causing an increase in intracellu-
lar Ca2+ and luminescence. We recently reported the use
of this assay to demonstrate that the luqin-type neuro-
peptide ArLQ acts as a ligand for the A. rubens G-
protein coupled receptors ArLQR1 and ArLQR2 [71],
and therefore, here only a brief outline of methods
employed is described. CHO-K1/G5A cells were trans-
fected with 5 μg of the pcDNA 3.1+ plasmid containing
the A. rubens VP/OT-type receptor cDNA and 1.5 μg of
plasmid containing an insert encoding the promiscuous
Gα16 subunit using the Lipofectamine 3000® Transfec-
tion Kit, (Invitrogen). The cells were then loaded with
the aqueorin substrate coelenterazine-H (Thermo Fisher
Scientific). Asterotocin at concentrations ranging from
10−4 to 10−12 M (n = 3) was pipetted into the wells of
clear-bottomed 96-well plates (Sigma-Aldrich), then a
FLUOstar Omega Plate Reader (BMG LABTECH) was
used to inject a fixed amount of transfected CHO-K1
cells into each well sequentially, and luminescence was
measured for a 35-s period after injection. Luminescence
measurements were normalised to the maximum re-
sponse obtained in each experiment (100%) and the re-
sponse obtained with the vehicle media (0%). These data
(three repeats per experiment and at least three inde-
pendent transfections) were used to construct a dose-
response curve utilising non-linear regression analysis in
Prism 6.0c (GraphPad, La Jolla, USA) and displayed on a
semi-logarithmic plot. The half maximal effective con-
centration (EC50) was calculated from the dose-response
curve in Prism 6.0c. For negative control experiments,
CHO-K1/G5A cells were transfected with the empty
pcDNA 3.1+ vector. Human vasopressin and oxytocin
and the A. rubens neuropeptide NGFFYamide were also
tested to assess the specificity of asterotocin as the can-
didate ligand for the A. rubens VP/OT-type receptor. A
Wilcoxon signed-rank test was performed to compare
luminescence of cells exposed to asterotocin, vasopres-
sin, oxytocin and NGFFYamide (at 10−4 M) with lumi-
nescence of cells in basal media (control).
Localisation of the expression asterotocin precursor and
asterotocin receptor transcripts in A. rubens using in situ
hybridisation
The method employed for the production of the astero-
tocin precursor antisense and sense digoxygenin (DIG)-
labelled RNA probes is as described in [22]. Production
of the asterotocin receptor antisense and sense DIG-
labelled RNA probes was performed as follows. The
plasmid containing the cloned asterotocin receptor
cDNA was linearised using the restriction enzymes Hin-
dIII and EcoRI (NEB, Hitchin, Hertfordshire, UK). Once
linearised, the plasmids were purified using phenol-
chloroform/chloroform isomylalcohol (Sigma-Aldrich
Ltd., Gillingham, UK) extraction. RNA probes were syn-
thesised from the purified, linearised plasmid using a
DIG-labelled nucleotide triphosphate mix (Roche, Nut-
ley, NJ) supplemented with dithiothreitol (Promega), a
placental RNase inhibitor (Promega), and RNA polymer-
ases (New England Biolabs), according to the manufac-
turer’s instructions. To synthesise the antisense and
sense probes, T3 and T7 RNA polymerases were used,
respectively. Reaction products were digested with
RNase-free DNase (New England Biolabs) to remove
template DNA and then stored in 25% formamide made
up in 2× saline-sodium citrate (SSC) buffer at − 20 °C.
The methods employed for preparation of sections
of 4% paraformaldehyde-fixed specimens of A. rubens
and visualisation of asterotocin precursor and astero-
tocin receptor transcripts in these sections were the
same as those used previously for the analysis of
AruRGPP expression, as reported in [72]. For the
visualisation of asterotocin precursor transcripts, the
sections were incubated with antisense and sense
RNA probes at a concentration of 800 ng/ml. Then,
following incubation with anti-DIG antibodies, slides
were incubated with the staining solution at room
temperature for a few hours until strong staining was
observed. For the visualisation of asterotocin receptor
transcripts, the sections were incubated with antisense
and sense RNA probes at a concentration of 1500 ng/ml.
Then, following incubation with anti-DIG antibodies,
the slides were incubated with the staining solution at
room temperature for a few hours, left overnight at
4 °C and then were incubated at room temperature
for several more hours until strong staining was
observed.
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Production, characterisation and purification of rabbit
antibodies to asterotocin and guinea pig antibodies to
the asterotocin receptor
To generate antibodies to asterotocin, a rabbit was
immunised with a conjugate of thyroglobulin (carrier
protein) and the peptide Lys-asterotocin
(KCLVQDCPEG-NH2; disulphide bridge between the
cysteine residues), with the N-terminal lysine provid-
ing a free amine group for glutaraldehyde-mediated
coupling to thyroglobulin. To generate antibodies to
the asterotocin receptor, a guinea pig was immunised
with a conjugate of thyroglobulin and a peptide cor-
responding to the C-terminal region of the asteroto-
cin receptor sequence (KFVSTTGTASAHM) but
with an additional N-terminal lysine providing a free
amine group for glutaraldehyde-mediated coupling to
thyroglobulin.
The peptide antigens were synthesised by Peptide
Protein Research Ltd. (Fareham, Hampshire, UK).
Conjugation of the antigen peptides to thyroglobulin
was performed as described in [20]. Rabbit immunisa-
tion and serum collection were performed by Charles
River Biologics (Romans, France) according to the fol-
lowing protocol. On day 0, pre-immune serum was
collected and the first immunisation (~ 100 nmol of
conjugated antigen peptide emulsified in Freund’s
complete adjuvant) was administered. Booster immu-
nisations (~ 50 nmol of conjugated antigen peptide
emulsified in Freund’s incomplete adjuvant) were ad-
ministered on days 28, 42 and 56. Samples of blood
serum were collected on days 38 and 52, and the
final bleed serum was collected on day 70. Guinea pig
immunisation and serum collection were performed
by Charles River Biologics (Romans, France) accord-
ing to the following protocol. On day 0, pre-immune
serum was collected and the first immunisation (~
100 nmol of conjugated antigen peptide emulsified in
Freund’s complete adjuvant) was administered.
Booster immunisations (~ 50 nmol of conjugated anti-
gen peptide emulsified in Freund’s incomplete adju-
vant) were administered on days 14, 28 and 42. A
serum sample was collected on day 38, and the final
bleed serum was collected on day 56.
Enzyme-linked immunosorbent assays (ELISA)
were performed to test the sera for the presence of
antibodies to the antigen peptides, employing the
same methods as described previously for ArGnRH
antisera [20]. Terminal bleed antisera were charac-
terised by ELISA by testing antisera at a starting di-
lution of 1:500 and subsequent twofold serial
dilutions down to 1:16,000 (Additional file 4). Then,
antibodies to the antigen peptides were affinity-
purified from terminal bleed antisera using Amino-
Link® Plus Immobilisation Kit (Thermo Scientific),
employing the same methods as described previously
for antibodies to ArGnRH [20].
Localisation of the expression of asterotocin and the
asterotocin receptor in A. rubens using
immunohistochemistry
The methods employed for preparation of sections of
Bouin’s fixed specimens A. rubens and immunohisto-
chemical localisation of asterotocin expression and aster-
otocin receptor expression were the same as those
described previously for ArPPLN1 and ArGnRH [21,
48]. The sections were incubated overnight or for 3 days,
respectively, with affinity-purified rabbit antibodies to
asterotocin (1:4 dilution) and guinea pig antibodies to
the asterotocin receptor (1:4 dilution). Then, bound anti-
bodies were visualised using diaminobenzidine as a sub-
strate for peroxidase-conjugated AffiniPure Goat anti-
rabbit immunoglobulins (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) or peroxidase-
conjugated AffiniPure Donkey anti-guinea pig immuno-
globulins (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA).
To visualise asterotocin and the asterotocin receptor
in the sections using double-labelling fluorescence im-
munohistochemistry, the sections were first incubated
with affinity-purified asterotocin antibodies (1:4 dilution)
overnight at 4 °C. Then, following washes (4 × 5min) in
phosphate-buffered saline (PBS) containing 0.1% Tween-
20 (PBST) and washes in PBS (4 × 10 min), the sections
were incubated with affinity-purified antibodies to the
asterotocin receptor (1:4 dilution) for 2 weeks at 4 °C.
Then, following washes with PBST and PBS (as de-
scribed above), the sections were incubated for 3 to 4 h
with Cy2-labelled goat anti-rabbit immunoglobulins and
Cy3-labelled goat anti-guinea pig immunoglobulins
(Jackson ImmunoResearch Europe Ltd., UK), which
were both diluted 1:200 in 2% normal goat serum in
PBS. Following washes in PBST and PBS (as described
above), the slides were mounted with coverslips using
Fluoroshield Mounting Medium with DAPI (Abcam,
Cambridge, UK).
To capture images of sections labelled using fluores-
cence immunohistochemistry, a Leica SP5 confocal
microscope was used in combination with the Leica Ap-
plication Suite Advanced Fluorescence (LAS AF; version
2.6.0.7266) programme. Argon and DPSS 561 lasers
were used for the detection of green fluorescence (aster-
otocin) and red fluorescence (asterotocin receptor), re-
spectively. For Beam Path Settings, FITC and TRITC
were selected, and in the case of TRITC, the PMT was
set to Cy3. While visualising immunofluorescence on
slides, the smart gain, smart offset and z position were
adjusted to generate optimal immunofluorescent images.
The settings for capturing images were as follows: image
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format, 1024 × 1024; scan speed, 200 Hz; frame average,
6; and line average accumulation, 3. The FITC and
TRITC images were taken separately, and the colour
channels were merged using ImageJ to produce double-
labelled images. Contrast and levels were adjusted in
ImageJ, and montages were created in Adobe Photoshop
CC 2017.1.1.
Analysis of the in vitro pharmacological effects of
asterotocin on cardiac stomach, apical muscle and tube
foot preparations from A. rubens
To investigate if asterotocin affects muscle contractility
in A. rubens, synthetic asterotocin (custom synthesised
by PPR Ltd., Fareham, Hampshire, UK) was tested on
three in vitro preparations: the cardiac stomach, apical
muscle and tube feet. These three preparations have
been used to examine the effects of other neuropeptides,
and the methods employed have been described in detail
previously [30, 33, 34, 73]. Preliminary tests revealed
that asterotocin caused relaxation of the cardiac stomach
and apical muscle preparations but had no effect on the
contractile state of tube foot preparations. Therefore, the
effects of asterotocin on cardiac stomach and apical
muscle preparations were examined in more detail.
Cardiac stomach preparations from 16 starfish (8–
13.5 cm in diameter) were incubated at 11 °C in an aer-
ated organ bath containing artificial seawater with 3 ×
10−2 M added KCl. This induces sustained contraction of
the cardiac stomach, which facilitates recording of the
effects of neuropeptides that act as muscle relaxants
[34]. The contractile state of preparations was monitored
using a high-grade isotonic transducer (model 60-3001;
Harvard Apparatus, Cambridge, UK) connected to a
Goerz SE 120 chart recorder (Recorderlab, Sutton, Sur-
rey, UK) or using a high-grade isotonic transducer
(MLT0015; ADInstruments Ltd., Oxford, UK) connected
to data acquisition hardware (PowerLab 2/26, ADInstru-
ments Ltd.) via a bridge amplifier (FE221 Bridge Amp,
ADInstruments Ltd.). The output from the PowerLab
was recorded using LabChart (v8.0.7) software installed
on a laptop computer (Lenovo E540, Windows 7 Profes-
sional). To obtain representative images of the effects of
asterotocin, traces were exported from LabChart into
Adobe Photoshop and the function ‘Select and Mask’
was utilised to remove the background grid pattern.
To investigate the dose dependence and potency of
asterotocin as a cardiac stomach relaxant, it was tested
at concentrations ranging from 3 × 10−11 M to 10−6 M
(n = 16). The percentage relaxation at each concentra-
tion was calculated relative to the maximal relaxing ef-
fect produced by asterotocin in each preparation. To
enable the assessment of the magnitude of the relaxing
effect of asterotocin on cardiac stomach, experiments
were performed to compare the effect asterotocin with
the effect of the neuropeptide SALMFamide-2 (S2;
SGPYSFNSGLTF-NH2), which has been shown previ-
ously to cause relaxation of A. rubens cardiac stomach
preparations in vitro [33, 34]. Having established that
the maximal relaxing effect of asterotocin is observed at
concentrations ranging from 3 × 10−9 M to 10−6 M (with
a mean of ~ 10−7 M), experiments were performed where
the effects of 10−7 M asterotocin and 10−7 M S2 on car-
diac stomach preparations (n = 5) were compared. For
these experiments, the effect of 10−7 M S2 was defined
as 100%, and the effect of 10−7 M asterotocin was calcu-
lated as a percentage of the effect of 10−7 M S2. The
relaxing effects of asterotocin and S2 on cardiac stomach
preparations were analysed statistically using the Mann-
Whitney U test.
To examine the effects of asterotocin on apical muscle
preparations, 10−6 M acetylcholine (ACh) was used to
induce contraction prior to application of asterotocin. A
relaxing effect of asterotocin was observed only at a high
concentration (10−6 M) and therefore it was not possible
to examine the dose dependency of this effect. However,
the experiments were performed in which the time
course of the relaxing effect of asterotocin was analysed
by measuring the percentage reversal of 10−6 M ACh-
induced contraction over a 50-s period after application
of 10−6 M asterotocin (n = 4).
Analysis of the in vivo effects of asterotocin on A. rubens
During feeding in A. rubens, the cardiac stomach is
everted out of the mouth over the digestible soft tissue
of prey (e.g. mussels), and to accomplish this, the cardiac
stomach must be relaxed. Previous studies have revealed
that S2, a neuropeptide that induces relaxation of A. ru-
bens cardiac stomach preparations in vitro, induces car-
diac stomach eversion when injected in vivo [34].
Having established that asterotocin causes relaxation of
cardiac stomach preparations in vitro, experiments were
performed to investigate if asterotocin also triggers car-
diac stomach eversion when injected in vivo. First, a
pilot experiment was performed using 30 starfish (diam-
eter 6.4–7.5 cm) that had been starved for 1 week to
normalise their physiological status. Then animals were
injected with different doses of asterotocin (10 μl of
10−6–10−3 M; n = 5 for each dose) or with 10 μl of water
(negative control; n = 5) or with 10 μl of 10−3 M S2 (posi-
tive control; n = 5). The animals were injected at a site
located in the aboral body wall of an arm proximal to
the junction with the central disc and adjacent to the
madreporite. Care was taken to ensure that the tip of a
Hamilton syringe used for injections was pushed
through the body wall into the perivisceral coelom but
not too deep so as to avoid injecting into the digestive
organs. The doses of asterotocin injected were informed
by our analysis of the volume of the perivisceral
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coelomic fluid in A. rubens. Thus, injection of 10 μl of
10−6–10−3 M asterotocin was estimated to achieve con-
centrations in the perivisceral coelom of ~ 10−9, 10−8,
10−7 and 10−6 M, respectively, which are the concentra-
tions at which asterotocin was found to be effective as a
cardiac stomach relaxant when tested in vitro. Following
injection, the starfish were placed in a glass vessel con-
taining seawater so that the mouth of the animal could
be observed from below.
Having established that asterotocin induced cardiac
stomach eversion in all of the animals injected with
10 μl 10−4 M or 10 μl 10−3 M asterotocin, an experiment
was performed to examine the time course of
asterotocin-induced cardiac stomach eversion in A. ru-
bens. For this experiment, 20 adult specimens of A. ru-
bens (13.1–17.1 cm in diameter) were selected and
starved for 1 week before the experiment. Then, the ani-
mals were injected with 10 μl of distilled water or 10 μl
of 10−3 M synthetic asterotocin. To enable observation
of cardiac stomach eversion, following injection, star-
fishes were placed individually in a petri dish containing
90ml of artificial seawater. A petri dish was used as it
has a shallow depth, which prevented the starfish from
climbing vertically and therefore enabling recording of
the whole oral surface of the starfish over time using a
video camera (Canon EOS 700D) positioned beneath the
petri dish. The oral surface of starfish was video re-
corded for 15 min, and static images from the video re-
cordings were captured at 30-s intervals from the time
of injection to 10 min post-injection, during which time
maximal stomach eversion was observed. The two-
dimensional area of the everted cardiac stomach was
measured from the images using the ImageJ software
and normalised as a percentage of the area of the central
disc of the animal, which was calculated as the area of a
circle linking the junctions between the five arms.
While examining the effect of asterotocin in inducing
cardiac stomach eversion in A. rubens, it was also ob-
served that asterotocin induced arm flexion and/or a
“humped” posture resembling the posture that starfish
have when feeding on prey. To investigate the influence
of this effect of asterotocin on whole-animal behaviour
in starfish, experiments were performed to compare the
righting behaviour of asterotocin-injected animals with
non-injected, water-injected and S2-injected animals.
Starfish righting behaviour occurs if they are upturned
so that their underside (oral surface) is uppermost. One
or more of the arms or rays then twist (active rays) until
the tube feet can make contact with and adhere to the
floor surface. Then, the other inactive rays and the cen-
tral disc are flipped over in a somersault-like manoeuvre
to bring the entire oral surface back into contact with
the floor surface [37, 74]. For an experiment investigat-
ing if asterotocin affects the righting behaviour of A.
rubens, 20 adult animals (10.2–14.9 cm in diameter)
were first starved for 1 week prior to the experiment to
normalise their physiological status. First, the righting
behaviour of starfish without injection was observed,
and if righting behaviour did not occur or took more
than 5min, the animal was categorised as unhealthy and
unsuitable for the experiment. Following a 30-min re-
covery period, starfish were either injected with 10 μl of
10−3 M asterotocin (n = 10) or 10 μl of distilled water
(n = 10). Then, after 5 min, each starfish was placed with
their oral side lowermost in a large glass container fully
immersed in artificial seawater for 10 min, after which
they were turned upside down with their oral side
uppermost and the time taken to right was measured.
For consistency, the time taken for righting was deter-
mined by noting when the central disc and all five arms
touched either the bottom or the side of the glass tank.
To examine the specificity of the effects of asterotocin
on starfish righting behaviour, an experiment was per-
formed where the righting time of starfish (5.5–9.6 cm
in diameter; starved for 4 weeks prior to testing) was
measured before injection (n = 60; pooled from the three
treatment groups) and after injection with 5 μl 10−3 M
asterotocin (n = 20) or 5 μl 10−3 M S2 (n = 20) or 5 μl
distilled water (n = 20). The time taken to right in
seconds as well as the percentage difference between
righting with and without injection was calculated. The
percentage time difference between righting with and
without injection in water-injected, asterotocin-injected
and S2-injected animals was determined and plotted as a
separated box and whiskers graph in Prism 6 (GraphPad
6). The effect of neuropeptides on righting behaviour
was analysed statistically using the Mann-Whitney U
test or a one-way ANOVA test with a post hoc Dunnett’s
multiple comparisons test.
Additional files
Additional file 1: Determination of the structure of asterotocin in A.
rubens using mass spectrometry (A). LC-ESI-MS/MS analysis of a synthetic
peptide (CLVQDCPEG-NH2) with the predicted structure of asterotocin re-
veals that it elutes with a retention time of 29.8 min and the deconvo-
luted, monoisotopic, singly charged spectrum derived from MS/MS data
for this peptide reveals a singly charged species at a m/z of 960.39, con-
sistent with the expected molecular mass. (B) LC-ESI-MS/MS analysis of an
extract of A. rubens radial nerve cords reveals the presence of a peptide
with identical retention time and a spectrum that is very similar to syn-
thetic asterotocin. Accurate mass measurement of the singly charged
species of the peptide was determined and mass error observed was
0.0002 Da (0.21 ppm). (TIF 9763 kb)
Additional file 2: Asterias rubens VP/OT-type receptor. The nucleotide
sequence (lowercase, 1510) of a cDNA encoding the receptor protein
(uppercase, 428 amino acid residues) is shown. Primers used for cloning
are represented in bold and underlined text. The asterisk denotes the
position of the stop codon. The predicted seven transmembrane
domains are highlighted in grey within the protein sequence. This cDNA
sequence is identical to part of a longer assembled transcript sequence
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(contig 1122053), which has been submitted to the GenBank database
under the accession number MK279533. (TIF 13215 kb)
Additional file 3: Species names and accession numbers for peptide
(Table S1) and receptor (Table S2) sequences in Figs. 1c and 2 a,
respectively. (DOCX 119 kb)
Additional file 4: Characterisation of antisera to asterotocin and the
asterotocin receptor using an enzyme-linked immunosorbent assay
(ELISA). (A) Incubation of rabbit antiserum (blue) at dilutions between
1:500 and 1:16,000 with 0.1 nmol of asterotocin antigen peptide per well
reveals that the antigen is detected at dilutions between 1:500 and
1:4000 by comparison with absorbance measurements for pre-immune
rabbit serum (undiluted; red) with 0.1 nmol antigen peptide (Lys-asteroto-
cin) per well. All data points are mean values from three replicates. (B) In-
cubation of guinea pig antiserum (green) at dilutions between 1:500 and
1:16,000 with 0.1 nmol of asterotocin receptor antigen peptide per well
reveals that the antigen is detected across the full range of dilutions
tested by comparison with absorbance measurements for pre-immune
guinea pig serum (undiluted; purple) with 0.1 nmol antigen peptide per
well. All data points are mean values from three replicates. (TIF 5347 kb)
Additional file 5: Immunohistochemical assessment of the specificity of
the asterotocin antiserum (A) Immunostaining in a transverse section of
a radial nerve cord that was incubated with asterotocin antiserum (1:1000
dilution). Immunoreactive cell bodies (arrowheads) can be seen in the
ectoneural epithelial layer and a dense network of stained fibres (asterisk)
can be seen in the neuropile of the ectoneural region of the radial nerve
cord. Staining can also be seen in the external epithelial layer of an
adjacent tube foot (arrow). (B) Immunostaining in a transverse section of
a radial nerve cord, adjacent to the section shown in (A), that was
incubated with antiserum (1:1000) that had been pre-absorbed with the
asterotocin antigen peptide (200 μM). Note that the majority of the im-
munostaining seen in (A) is absent in (B), but there is some residual stain-
ing in the ectoneural epithelial layer of the radial nerve cord
(arrowheads) and in the epithelial layer of the adjacent tube foot (arrow).
Therefore, antibodies to asterotocin were affinity-purified from the anti-
serum and used for the immunohistochemical analysis of asterotocin ex-
pression shown in Fig. 4. Abbreviations: Ec, ectoneural region; Hy,
hyponeural region; TF, tube foot. Scale bars: (A) and (B) = 40 μm.
(TIF 5965 kb)
Additional file 6: Raw values where data are based on smaller sample
sizes. Table S1: Raw data for Fig. 7c inset, which compares the relaxing
effects of asterotocin and S2 on cardiac stomach preparations; n = 5.
Table S2: Raw data for Fig. 7d inset, which shows the mean percentage
reversal of ACh-induced contraction of apical muscle preparations caused
by asterotocin; n = 4. (XLSX 33 kb)
Additional file 7: Video recording showing asterotocin-induced cardiac
stomach eversion in A. rubens. The video on the left shows that no car-
diac stomach eversion is observed in a control animal that had been
injected with 10 μl water. The video on the right shows that cardiac
stomach eversion is observed in an animal that had been injected with
10 μl of 10−3 M asterotocin. These videos are representative of the experi-
ments shown in Fig. 8, and static images from these videos are shown in
Fig. 8c. The original video recordings were 12 min in length, and these
were then sped up to 45-s videos and combined into a single file using
Final Cut Pro software. (MP4 12041 kb)
Acknowledgements
We are grateful to Phil Edwards for his help with obtaining starfish and to
Paul Fletcher for maintaining our seawater aquarium.
Authors’ contributions
MRE, EAO and DCS were responsible for the study concept and design. EAO
and DCS were responsible for the acquisition of data and cloning of cDNAs
encoding asterotocin precursor and asterotocin receptor. SES, JHS, DCS and
MRE were responsible for the determination of the structure of asterotocin.
EAO was responsible for the pharmacological characterisation of the
asterotocin receptor. EAO, ME and DCS were responsible for the localisation
of asterotocin precursor and asterotocin receptor expression using mRNA in
situ hybridisation and immunohistochemistry. NM, EAO and DCS were
responsible for the in vitro pharmacology. EAO, ABT, DCS, AKG, RRP, LMB, MZ
and JD were responsible for the in vivo pharmacology. EAO, DCS, ABT and
MRE were responsible for the analysis and interpretation of the data. ME was
responsible for the technical and material support. EAO and MRE were
responsible for writing of the first draft of the manuscript. MRE was
responsible for the study supervision. All authors read and approved the final
manuscript.
Funding
The research reported in this paper was funded by a PhD studentship
awarded to EAO by the Society for Experimental Biology, grants from the
BBSRC (BB/M001644/1) and Leverhulme Trust (RPG-2013-351, RPG-2018-200)
awarded to MRE and a grant from the BBSRC (BB/M001032/1) awarded to
JHS.
Availability of data and materials
All datasets generated or analysed during this study are included in this
published article [and its supplementary information files] or are available
from the corresponding author on reasonable request. Accession numbers
for NCBI, GenBank and UniProt peptides for the peptide sequences in Fig. 1c
and the receptor sequences used in Fig. 2a can be found in Tables S1 and
S2, respectively, in Additional file 3.





The authors declare that they have no competing interests.
Author details
1School of Biological & Chemical Sciences, Queen Mary University of London,
Mile End Road, London E1 4NS, UK. 2Waters/Warwick Centre for BioMedical
Mass Spectrometry and Proteomics, School of Life Sciences, University of
Warwick, Coventry CV4 7AL, UK. 3Department of Clinical Neurosciences, MRC
Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0SZ,
UK. 4Department of Neuroscience, Brown University, Providence, USA.
5Research Institute for Biosciences, Biology of Marine Organisms and
Biomimetics, University of Mons (UMONS), 7000 Mons, Belgium. 6Waters
Corporation, Stamford Avenue, Altrincham Road, Wilmslow SK9 4AX, UK.
7School of Science, Engineering & Design, Teesside University, Stephenson
Street, Tees Valley TS1 3BA, UK.
Received: 29 March 2019 Accepted: 9 July 2019
References
1. Jekely G, Melzer S, Beets I, Kadow ICG, Koene J, Haddad S, et al. The long
and the short of it - a perspective on peptidergic regulation of circuits and
behaviour. J Exp Biol. 2018;221(Pt 3):1-14.
2. van den Pol AN. Neuropeptide transmission in brain circuits. Neuron. 2012;
76(1):98–115.
3. Elphick MR, Mirabeau O, Larhammar D. Evolution of neuropeptide signalling
systems. J Exp Biol. 2018;221(Pt 3):1-15.
4. Sawyer WH. Evolution of neurohypophyseal hormones and their receptors.
Fed Proc. 1977;36(6):1842–7.
5. Johnson ZV, Young LJ. Oxytocin and vasopressin neural networks:
implications for social behavioral diversity and translational neuroscience.
Neurosci Biobehav Rev. 2017;76(Pt A):87–98.
6. Mirabeau O, Joly JS. Molecular evolution of peptidergic signaling systems in
bilaterians. Proc Natl Acad Sci U S A. 2013;110(22):E2028–37.
7. Jekely G. Global view of the evolution and diversity of metazoan
neuropeptide signaling. Proc Natl Acad Sci U S A. 2013;110(21):8702–7.
8. Cruz LJ, de Santos V, Zafaralla GC, Ramilo CA, Zeikus R, Gray WR, et al.
Invertebrate vasopressin/oxytocin homologs. Characterization of peptides
from conus geographus and Conus straitus venoms. J Biol Chem. 1987;
262(33):15821–4.
9. Proux JP, Miller CA, Li JP, Carney RL, Girardie A, Delaage M, et al.
Identification of an arginine vasopressin-like diuretic hormone from Locusta
migratoria. Biochem Biophys Res Commun. 1987;149(1):180–6.
Odekunle et al. BMC Biology           (2019) 17:60 Page 21 of 23
10. Beets I, Temmerman L, Janssen T, Schoofs L. Ancient neuromodulation by
vasopressin/oxytocin-related peptides. Worm. 2013;2(2):e24246.
11. Gruber CW. Physiology of invertebrate oxytocin and vasopressin
neuropeptides. Exp Physiol. 2014;99(1):55–61.
12. Lockard MA, Ebert MS, Bargmann CI. Oxytocin mediated behavior in
invertebrates: an evolutionary perspective. Dev Neurobiol. 2017;77(2):128–42.
13. Aikins MJ, Schooley DA, Begum K, Detheux M, Beeman RW, Park Y.
Vasopressin-like peptide and its receptor function in an indirect diuretic
signaling pathway in the red flour beetle. Insect Biochem Mol Biol. 2008;
38(7):740–8.
14. Van Kesteren RE, Smit AB, Dirks RW, De With ND, Geraerts WPM, Joosse
J. Evolution of the vasopressin/oxytocin superfamily: characterization of
a cDNA encoding a vasopressin-related precursor, preproconopressin,
from the mollusc Lymnaea stagnalis. Proc Natl Acad Sci U S A. 1992;89:
4593–7.
15. Van Kesteren RE, Smit AB, De Lange RPJ, Kits KS, Van Golen FA, Van Der
Schors RC, et al. Structural and functional evolution of the vasopressin/
oxytocin superfamily: vasopressin-related conopressin is the only member
present in Lymnaea, and is involved in the control of sexual behavior. J
Neurosci. 1995;15(9):5898–998.
16. Garrison JL, Macosko EZ, Bernstein S, Pokala N, Albrecht DR, Bargmann CI.
Oxytocin/vasopressin-related peptides have an ancient role in reproductive
behavior. Science. 2012;338(6106):540–3.
17. Holland P. The animal kingdom: a very short introduction: Oxford University
Press; 2011. 144 p.
18. Elphick MR, Rowe ML. NGFFFamide and echinotocin: structurally unrelated
myoactive neuropeptides derived from neurophysin-containing precursors
in sea urchins. J Exp Biol. 2009;212:1067–77.
19. Semmens DC, Mirabeau O, Moghul I, Pancholi MR, Wurm Y, Elphick MR.
Transcriptomic identification of starfish neuropeptide precursors yields new
insights into neuropeptide evolution. Open Biol. 2016;6(2):150224.
20. Tian S, Zandawala M, Beets I, Baytemur E, Slade SE, Scrivens JH, et al.
Urbilaterian origin of paralogous GnRH and corazonin neuropeptide
signalling pathways. Sci Rep. 2016;6:28788.
21. Tian S, Egertová M, Elphick MR. Functional characterization of paralogous
gonadotropin-releasing hormone-type and corazonin-type neuropeptides in
an echinoderm. Front Pharmacol. 2017;8:259.
22. Mayorova TD, Tian S, Cai W, Semmens DC, Odekunle EA, Zandawala M, et
al. Localization of neuropeptide gene expression in larvae of an
echinoderm, the starfish Asterias rubens. Front Neurosci. 2016;10:553.
23. Acher R, Chauvet J. La structure de la vasopressine de boeuf. Biochim
Biophys Acta. 1954;14:421–9.
24. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. The
synthesis of oxytocin. J Am Chem Soc. 1954;76(12):3115–21.
25. Semmens DC, Beets I, Rowe ML, Blowes LM, Oliveri P, Elphick MR. Discovery
of sea urchin NGFFFamide receptor unites a bilaterian neuropeptide family.
Open Biol. 2015;5(4):150030.
26. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K-I, Kusayama T, et al.
Pharmacological characterization of the human vasopressin receptor
subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol.
1998;125(7):1463–70.
27. Kawada T, Sekiguchi T, Itoh Y, Ogasawara M, Satake H. Characterization of a
novel vasopressin/oxytocin superfamily peptide and its receptor from an
ascidian, Ciona intestinalis. Peptides. 2008;29(10):1672–8.
28. Kawada T, Kanda A, Minakata H, Matsushima O, Satake H. Identification of a
novel receptor for an invertebrate oxytocin/vasopressin superfamily peptide:
molecular and functional evolution of the oxytocin/vasopressin superfamily.
Biochem J. 2004;382(Pt 1):231–7.
29. Beets I, Janssen T, Meelkop E, Temmerman L, Suetens N, Rademakers S, et
al. Vasopressin/oxytocin-related signaling regulates gustatory associative
learning in C. elegans. Science. 2012;338(6106):543–5.
30. Semmens DC, Dane RE, Pancholi MR, Slade SE, Scrivens JH, Elphick MR.
Discovery of a novel neurophysin-associated neuropeptide that triggers
cardiac stomach contraction and retraction in starfish. J Exp Biol. 2013;
216(21):4047–53.
31. Tinoco AB, Semmens DC, Patching EC, Gunner EF, Egertova M, Elphick MR.
Characterization of NGFFYamide signaling in starfish reveals roles in
regulation of feeding behavior and locomotory systems. Front Endocrinol
(Lausanne). 2018;9:507.
32. Mashanov V, Zueva O, Rubilar T, Epherra L, Garcia-Arraras JE. Echinodermata.
In: Schmidt-Rhaesa A, Harzsch S, Purschke G, editors. Structure and
evolution of invertebrate nervous systems. Oxford: Oxford University Press;
2016. p. 665–88.
33. Elphick MR, Newman SJ, Thorndyke MC. Distribution and action of
SALMFamide neuropeptides in the starfish Asterias rubens. J Exp Biol. 1995;
198(Pt 12):2519–25.
34. Melarange R, Potton DJ, Thorndyke MC, Elphick MR. SALMFamide
neuropeptides cause relaxation and eversion of the cardiac stomach in
starfish. Proc R Soc Lond Ser B Biol Sci. 1999;266(1430):1785–9.
35. Anderson JM. Studies on the cardiac stomach of the starfish Asterias forbesi.
Biol Bull. 1954;107:157–73.
36. Lavoie ME. How sea stars open bivalves. Biol Bull. 1956;111(1):114–22.
37. Romanes GJ, Ewart JC. The Croonian Lecture. - Observations on the
locomotor system of Echinodermata. Philos Trans R Soc Lond. 1881;172:
829–85.
38. Cole LJ. Experiments on coordination and righting in the starfish. Biol Bull.
1913;24(5):362–9.
39. Semmens DC, Elphick MR. The evolution of neuropeptide signalling:
insights from echinoderms. Brief Funct Genomics. 2017;16(5):288–98.
40. Oliver G, Schafer EA. On the physiological action of extracts of pituitary
body and certain other glandular organs: preliminary communication. J
Physiol. 1895;18(3):277–9.
41. Dale HH. The action of extracts of the pituitary body. Biochem J. 1909;4(9):
427–47.
42. Takuwa-Kuroda K, Iwakoshi-Ukena E, Kanda A, Minakata H. Octopus, which owns
the most advanced brain in invertebrates, has two members of vasopressin/
oxytocin superfamily as in vertebrates. Regul Pept. 2003;115(2):139–49.
43. Oumi T, Ukena K, Matsushima O, Ikeda T, Fujita T, Minakata H, et al.
Annetocin, an annelid oxytocin-related peptide, induces egg-laying
behavior in the earthworm, Eisenia foetida. J Exp Zool. 1996;276(2):151–6.
44. Ukena K, Iwakoshi-Ukena E, Hikosaka A. Unique form and osmoregulatory
function of a neurohypophysial hormone in a urochordate. Endocrinology.
2008;149(10):5254–61.
45. Smith JE. The motor nervous system of the starfish, Astropecten
irregularis (pennant), with special reference to the innervation of the
tube feet and ampullae. Philos Trans R Soc Lond Ser B Biol Sci. 1950;
234(618):521–58.
46. Pentreath VW, Cobb JL. Neurobiology of echinodermata. Biol Rev Camb
Philos Soc. 1972;47(3):363–92.
47. Blowes LM, Egertova M, Liu Y, Davis GR, Terrill NJ, Gupta HS, et al. Body wall
structure in the starfish Asterias rubens. J Anat. 2017;231(3):325–41.
48. Lin M, Egertova M, Zampronio CG, Jones AM, Elphick MR. Pedal peptide/
orcokinin-type neuropeptide signaling in a deuterostome: the anatomy and
pharmacology of starfish myorelaxant peptide in Asterias rubens. J Comp
Neurol. 2017;525(18):3890–917.
49. Lin M, Egertova M, Zampronio CG, Jones AM, Elphick MR. Functional
characterization of a second pedal peptide/orcokinin-type neuropeptide
signaling system in the starfish Asterias rubens. J Comp Neurol. 2018;526(5):
858–76.
50. Cai W, Kim CH, Go HJ, Egertova M, Zampronio CG, Jones AM, et al.
Biochemical, anatomical, and pharmacological characterization of calcitonin-
type neuropeptides in starfish: discovery of an ancient role as muscle
relaxants. Front Neurosci. 2018;12:382.
51. Balment RJ, Lu W, Weybourne E, Warne JM. Arginine vasotocin a key
hormone in fish physiology and behaviour: a review with insights from
mammalian models. Gen Comp Endocrinol. 2006;147(1):9–16.
52. Leslie M, Silva P, Paloyelis Y, Blevins J, Treasure J. A systematic review and
quantitative meta-analysis of oxytocin’s effects on feeding. J
Neuroendocrinol. 2018;30:e12584.
53. Skinner JA, Campbell EJ, Dayas CV, Garg ML, Burrows TL. The relationship
between oxytocin, dietary intake and feeding: a systematic review and
meta-analysis of studies in mice and rats. Front Neuroendocrinol. 2019;52:
65-78.
54. Spetter MS, Hallschmid M. Current findings on the role of oxytocin in the
regulation of food intake. Physiol Behav. 2017;176:31–9.
55. Lawson EA. The effects of oxytocin on eating behaviour and metabolism in
humans. Nat Rev Endocrinol. 2017;13(12):700–9.
56. Holmes GM, Browning KN, Babic T, Fortna SR, Coleman FH, Travagli RA.
Vagal afferent fibres determine the oxytocin-induced modulation of gastric
tone. J Physiol. 2013;591(12):3081–100.
57. Richard P, Moos F, Freund-Mercier MJ. Central effects of oxytocin. Physiol
Rev. 1991;71(2):331–70.
Odekunle et al. BMC Biology           (2019) 17:60 Page 22 of 23
58. Mennigen JA, Volkoff H, Chang JP, Trudeau VL. The nonapeptide isotocin in
goldfish: evidence for serotonergic regulation and functional roles in the
control of food intake and pituitary hormone release. Gen Comp
Endocrinol. 2017;254:38–49.
59. Gesto M, Soengas JL, Rodriguez-Illamola A, Miguez JM. Arginine vasotocin
treatment induces a stress response and exerts a potent anorexigenic effect
in rainbow trout, Oncorhynchus mykiss. J Neuroendocrinol. 2014;26(2):89–99.
60. Oumi T, Ukena K, Matsushima O, Ikeda T, Fujita T, Minakata H, et al.
Annetocin: an oxytocin-related peptide isolated from the earthworm,
Eisenia foetida. Biochem Biophys Res Commun. 1994;198(1):393–9.
61. Kanda A, Satake H, Kawada T, Minakata H. Novel evolutionary lineages of
the invertebrate oxytocin/vasopressin superfamily peptides and their
receptors in the common octopus (Octopus vulgaris). Biochem J. 2005;
387(Pt 1):85–91.
62. Kanda A, Takuwa-Kuroda K, Iwakoshi-Ukena E, Furukawa Y, Matsushima O,
Minakata H. Cloning of Octopus cephalotocin receptor, a member of the
oxytocin/vasopressin superfamily. J Endocrinol. 2003;179(2):281–91.
63. Chaet AB. A mechanism for obtaining mature gametes from starfish. Biol
Bull. 1964;126(1):8–13.
64. Elphick MR, Price DA, Lee TD, Thorndyke MC. The SALMFamides: a new
family of neuropeptides isolated from an echinoderm. Proc Biol Sci. 1991;
243(1307):121–7.
65. Burke RD, Angerer LM, Elphick MR, Humphrey GW, Yaguchi S, Kiyama T, et
al. A genomic view of the sea urchin nervous system. Dev Biol. 2006;300(1):
434–60.
66. Priyam A, Woodcroft BJ, Rai V, Munagala A, Moghul I, Ter F, et al.
Sequenceserver: a modern graphical user interface for custom BLAST
databases. bioRxiv. 2015;033142.
67. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics
analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–4.
68. Talavera G, Castresana J. Improvement of phylogenies after removing
divergent and ambiguously aligned blocks from protein sequence
alignments. Syst Biol. 2007;56(4):564–77.
69. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New
algorithms and methods to estimate maximum-likelihood phylogenies:
assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307–21.
70. Baubet V, Le Mouellic H, Campbell AK, Lucas-Meunier E, Fossier P, Brûlet P.
Chimeric green fluorescent protein-aequorin as bioluminescent Ca(2+)
reporters at the single-cell level. Proc Natl Acad Sci U S A. 2000;97(13):7260–5.
71. Yañez-Guerra LA, Delroisse J, Barreiro-Iglesias A, Slade SE, Scrivens JH,
Elphick MR. Discovery and functional characterisation of a luqin-type
neuropeptide signalling system in a deuterostome. Sci Rep. 2018;8(1):7220.
72. Lin M, Mita M, Egertová M, Zampronio Cleidiane G, Jones Alexandra M,
Elphick MR. Cellular localization of relaxin-like gonad-stimulating peptide
expression in Asterias rubens: new insights into neurohormonal control of
spawning in starfish. J Comp Neurol. 2017;525(7):1599–617.
73. Melarange R, Elphick MR. Comparative analysis of nitric oxide and
SALMFamide neuropeptides as general muscle relaxants in starfish. J Exp
Biol. 2003;206(5):893.
74. Hamilton WF. Coordination in the starfish. III. The righting reaction as a
phase of locomotion (righting and locomotion). J Comp Psychol. 1922;2(2):
81–94.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Odekunle et al. BMC Biology           (2019) 17:60 Page 23 of 23
